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Background: In recent years, non-Laboratory based (non-LB) risk assessment 
algorithms have been developed to facilitate absolute cardiovascular disease (CVD) risk 
assessment in resource constrained primary care settings. The non-LB Framingham 
algorithm, which substitutes body mass index (BMI) for lipids, has the best 
discrimination and calibration among the published algorithms, but its external validity 
and cost-effectiveness have not been determined.  
Purpose: External validation and comparative effectiveness analysis of the non-
LB versus laboratory based (LB) Framingham algorithm in a racially diverse population, 
and simulated cost-effectiveness analysis focusing on a black sample. 
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Methods: Secondary data analysis was performed using the Atherosclerosis Risk 
in Communities (ARIC) dataset. Cox regression models including the non-LB and LB 
Framingham covariates were developed. Model discrimination was assessed using the C 
statistic, calibration using the goodness-of-fit test, and equivalence of regression 
coefficients using the z-test. Algorithms based on the models were developed and their 
performance assessed using the area under receiver operating characteristic curve 
(AUROC), and agreement using kappa statistics. Analyses using simulated incremental 
cost-effectiveness ratios (ICER) were focused on the black sample. IRB approval was 
obtained. Data were analyzed using Stata© software version 14. 
Results: Among 11,601 individuals (mean age 53.9 ± 5.7 years, 55% female, 24% 
black), the non-LB versus LB models performed as follows: C statistic (0.75 vs 0.76 for 
women, & 0.67 vs 0.68 for men); goodness-of-fit (14.2 vs 10.5 for women, & 25.8 vs 
21.8 for men) respectively. In the black sample, regression coefficients of all covariates 
were similar to those generated in Framingham (z = ±1.96). The two algorithms based on 
the models had a kappa statistic of 0.76. When used to stratify risk in the entire ARIC 
sample, the non-LB and LB Framingham algorithms had AUROC of 0.706 vs 0.710 
respectively. Prevention program guided by the non-LB Framingham dominated those 
guided by individual risk factors and LB Framingham algorithm. 
Conclusions: These results demonstrate the validity and cost-effectiveness of the 
non-LB Framingham algorithm.  This approach could provide a valuable and efficient 
alternative to the traditional LB approaches in the ongoing efforts to address the high 





This work was supported by an award from the American Heart Association. 
 
The dissertation was prepared using ARIC Research Materials obtained from the NHLBI 
Biologic Specimen and Data Repository Information Coordinating Center and does not 
necessarily reflect the opinions or views of the ARIC or the NHLBI. 
DEDICATION 
I dedicate this work to the memory of my late grandmother, Wanjiru Kigo, 
 who taught me the essence of life essentials. 
To the love of my life, Kageha, for all the sacrifices you made. 
To my parents and many siblings for the incredible support I can’t even begin to quantify. 
To my church community and Almighty God, for the inspiration to a life with a purpose. 
 I wish to thank my committee members Drs. Eileen Stuart-Shor, Suzanne 
Leveille, Phil Gona and Jerry Cromwell for their extraordinary support and commitment 
to bring the best out of me. A special thanks to Dr. Eileen Stuart-Shor, my committee 
chairperson for her mentorship and encouragement throughout my graduate training. 
Thank you to my professors, classmates and friends who inspired me to keep questioning 










TABLE OF CONTENTS 
 
ACKNOWLEDGMENTS/ DEDICATION ................................................... vi 
 
LIST OF TABLES ......................................................................................... xi 
 
LIST OF FIGURES ....................................................................................... xiv 
 
LIST OF ABBREVIATIONS ........................................................................ xviii 
 
CHAPTER                                                                                                           Page 
 
 1. INTRODUCTION ......................................................................... 1 
  Goals of the Study .................................................................. 4  
  Significance and Innovation .................................................. 5 
  Defining Key terms ................................................................ 5 
  Conceptual Framework .......................................................... 6 
        The Conceptual Theoretical and Empirical (CTE)  
        structure............................................................................ 10 
 
 2. LITERATURE REVIEW .............................................................. 12 
  Background: absolute CVD risk assessment ......................... 12 
  The impact of CVD in resource constrained settings ............ 17 
  Preventing CVD in resource constrained settings ................. 20 





 3. RESEARCH DESIGN AND METHODS ..................................... 22 
   Overview ................................................................................ 22 
  Baseline assessment ............................................................... 25 
  Follow-up assessment ............................................................ 26 
  Statistical analyses ................................................................. 28 
         Analysis plan by study aims ........................................... 29 
          Cost-effectiveness analysis  ............................................ 31 
  Case example: individual vs absolute CVD risk approach .... 37 
  Absolute versus individual risk decision model .................... 38 
         Cost-effectiveness framework ........................................ 41 
         Interpreting the ICER ...................................................... 42 
 
 4. RESULTS ...................................................................................... 44 
  a) Sample description ............................................................. 45 
                   Incident CVD during 12 years of follow-up .................... 47 
  b) Mathematical models’ performance .................................. 49 
   The unadjusted non-LB Framingham models.................. 50 
   The unadjusted LB Framingham models ......................... 54 
   The adjusted non-LB models ........................................... 58 
   The adjusted non-LB models ........................................... 60 








             c) Applicability of the Framingham algorithms in 
      the ARIC sample ................................................................ 62 
   CVD risk stratification using the frozen Framingham 
    algorithms ....................................................................... 62 
   CVD risk stratification using the recalibrated 
   algorithms ........................................................................ 67 
   CVD risk stratification using the recalibrated  
   algorithms ........................................................................ 69 
  d) Sensitivity/specificity analysis .......................................... 71  
       Sensitivity/specificity analysis of the frozen  
   Framingham algorithms ................................................... 71 
       The frozen non-LB Framingham algorithm ................. 72 
       The frozen LB Framingham algorithm ........................ 75 
   Sensitivity/specificity analysis of the recalibrated  
   algorithms ........................................................................ 78 
       The recalibrated non-LB algorithm ............................. 78 
       The recalibrated LB algorithm ..................................... 79 
   Sensitivity/specificity analysis of the adjusted 
   algorithms ........................................................................ 81 
       The adjusted non-LB algorithm ................................... 81 
       The adjusted LB algorithm .......................................... 82 








       e) Simulated cost-effectiveness analysis of the non-LB 
        Framingham algorithm ...................................................... 86 
    Introduction ...................................................................... 86 
    Level I:  Expenses in screening for CVD ........................ 86 
    Level II:  Expenses of initial and follow-up visits  
    for positive cases .............................................................. 89 
       Costs associated with initial office visits ...................... 93 
               Costs associated with follow-up office visits................ 94 
       Costs associated preventive interventions .................... 98 
              The Individual CVD risk factors strategy 
           treatment expenses .................................................... 98 
                The non-LB absolute CVD risk strategy  
            treatment costs: ........................................................ 101 
            The LB absolute CVD risk strategy  
            treatment costs: ........................................................ 106 
                  Summary of level I and II expenses ......................... 110 
    Level III:  Expenses in treating false negatives  
    cases ................................................................................. 110 
                        Summary of level III expenses ................................. 113 
    Outcomes associated with the three prevention 
     programs ......................................................................... 113 
     Average and incremental cost effectiveness ........................ 116 
    The average cost-effectiveness ratio ................................ 116 






5. DISCUSSION .................................................................................... 119 
 
        Social determinants of health and CVD risk 
        assessment  ................................................................................ 119 
      
        Incidence of CVD by sex and race  .......................................... 120 
 
        Performance of the non-LB Framingham CVD risk  
        assessment algorithm ................................................................ 121 
    Comparative performance in risk stratification ............... 126 
       Cost-effectiveness of non-LB Framingham Algorithm ............. 129 
          Possible relevance to sub-Saharan Africa (SSA) ...................... 132 
          Conclusion ................................................................................ 134 
 




















LIST OF TABLES 
 
       Table                                                                                                   Page 
 
1. Sample characteristics and end points used in Framingham  
versus ARIC cohorts .................................................................... 16 
 
2. WHO choice & intensity of CVD prevention strategy guided  
by absolute CVD risk ................................................................... 36 
 
3.1 Baseline characteristics stratified by eligibility criteria ............... 46 
  
 3.2 Baseline characteristics of the eligible sample 
 stratified by sex ........................................................................... 46 
 
4. Regression beta coefficients of the unadjusted non-LB  
Framingham in ARIC and z test score of equality ....................... 52 
 
5. Regression beta coefficients of the unadjusted LB  
Framingham in ARIC and z test score of equality ....................... 55 
 
 
6. Regression beta coefficients of the adjusted non-LB model  
stratified by sex and race.............................................................. 59 
 
 
7. Regression beta coefficients of the adjusted LB model  





8. Kappa test frozen non-LB versus LB Framingham algorithm’s 
risk categories .............................................................................. 65 
 
9. Sensitivity/specificity analysis of the frozen non-LB Framingham 
 algorithm ...................................................................................... 72 
 
 
10. Sensitivity/specificity analysis of the frozen LB Framingham 
algorithm ....................................................................................... 75 
 
 
11. Sensitivity/specificity analysis of recalibrated non-LB 
algorithm ....................................................................................... 78 
 
 
12. Sensitivity/specificity analysis of recalibrated LB 
algorithm ....................................................................................... 80 
 
 
13. Sensitivity/specificity analysis of the adjusted non-LB 
algorithm ....................................................................................... 81 
 
 
14. Sensitivity/specificity analysis of the adjusted LB 
algorithm ....................................................................................... 83 
 
 
15. Marginal screening costs: individual risk factors vs  
absolute non-LB vs LB absolute risk approach ........................... 89 
 
 
16. Sensitivity/specificity analysis of the individual risk factors 
 strategy ........................................................................................ 90 
 
 
17. Sensitivity/specificity analysis of the non-LB guided  





18. Sensitivity/specificity analysis of the LB guided  
absolute CVD risk strategy ........................................................... 92 
 
 
19. Discounted costs of follow-up office visits: individual risk factors 
 vs absolute non-LB vs LB absolute risk approach ...................... 97 
 
 
20. Discounted costs of preventive interventions: individual risk factors 
 vs absolute non-LB vs LB absolute risk approach ...................... 109 
 
21. Initial & follow-up costs for treating false negative cases 
 by prevention strategy ................................................................. 112 
 
 






























LIST OF FIGURES 
 
Figure 
                                                                                                  Page 
1. The Social Ecological & Chronic Care Model  
adapted to focus on CVD ............................................................. 11 
 
2. Flowchart of inclusion and exclusion criteria and monitored  
outcomes ...................................................................................... 24 
 
3. CVD prevention strategy based on treating diabetes/hypertension  
to target goals ............................................................................... 34 
 
4.1 Events trajectories associated with three CVD  
prevention strategies .................................................................... 40 
 
4.2 Cost-effectiveness plane depicting acceptability  
of ICER ratios .............................................................................. 43 
 
5. General & cause specific CVD incidence rate in ARIC  
stratified by sex & race ................................................................ 48 
  
6. General & case specific CVD incidence proportion in ARIC  
stratified by sex & race ................................................................ 49 
 
7. Calibration- unadjusted non-LB based Framingham women 
 specific model ............................................................................. 53 
 
 
8. Calibration- unadjusted non-LB based Framingham men 





9. Calibration- unadjusted LB Framingham women  
specific model .............................................................................. 57 
 
 
10. Calibration- unadjusted LB Framingham men  
specific model .............................................................................. 57 
 
11. Risk stratification in ARIC cohort as per the Frozen non-LB 
 Framingham ................................................................................ 64 
 
 
12. Risk stratification in ARIC cohort as per the Frozen LB 
 Framingham ................................................................................ 64 
 
 
13. Frozen non-LB Framingham algorithm risk categories  
stratified by sex & race ................................................................ 66 
 
 
14. Frozen LB Framingham algorithm risk categories  
stratified by sex & race ................................................................ 67 
 
 
15. Recalibrated non-LB algorithm risk categories  
stratified by sex & race ................................................................ 68 
 
 
16. Recalibrated LB algorithm risk categories  
stratified by sex & race ................................................................ 69 
 
 
17. Adjusted non-LB algorithm risk categories  
stratified by sex & race ................................................................ 70 
 
 
18. Adjusted LB algorithm risk categories  
xvii 
 
stratified by sex & race ................................................................ 71 
 
 
19. Frozen non-LB Framingham AUROC for 
 entire ARIC sample..................................................................... 73 
 
 
20. Frozen non-LB Framingham AUROC white women           ............ 74 
 
21. Frozen non-LB Framingham AUROC black women           ............ 74 
 
 
22. Frozen non-LB Framingham AUROC white men           ................ 74 
 
23. Frozen non-LB Framingham AUROC black men .......................... 74 
 
 
24. Frozen LB Framingham AUROC for entire ARIC sample ............. 76 
 
25. Comparing frozen Framingham algorithms’ AUROCs in 
entire ARIC sample ....................................................................... 76 
 
26. Frozen LB Framingham AUROC white women           ................... 77 
 
27. Frozen LB Framingham AUROC black women           ................... 77 
 
 
28. Frozen LB Framingham AUROC white men           ....................... 77 
 
29. Frozen LB Framingham AUROC black men ................................. 77 
 
 
30. Recalibrated non-LB Framingham AUROC for  




31. Recalibrated LB Framingham AUROC for  
entire ARIC sample...................................................................... 80 
32. Adjusted non-LB algorithm AUROC for  
entire ARIC sample...................................................................... 82 
 
33. Adjusted LB algorithm AUROC for  
entire ARIC sample...................................................................... 83 
 
 
34. Comparing all non-LB algorithms     ........................................... 85 
35. Comparing all LB algorithms     .................................................. 85 
 
 
36. Comparing frozen LB with all non-LB based algorithms     ....... 85 
 




























LIST OF ABBREVIATIONS 
 
 
CVD: Cardiovascular disease 
LB: Laboratory 
ICER: Incremental cost-effectiveness ratio 









Cardiovascular disease (CVD), including coronary heart disease and stroke, is 
now the leading cause of death globally due in part to the ongoing epidemiological 
transition from infectious to non-communicable diseases in developing countries (WHO, 
2015). Currently over 75% of all CVD deaths occur in developing countries where CVD 
is taking toll on populations in resource constrained settings who rely on under-developed 
health care systems that are traditionally invested in treating infectious diseases (Mensah, 
2008; WHO, 2015). Consequently, most of the CVD mortality and morbidity occur at 
younger ages in these countries (S. Mendis et al., 2007; WHO, 2015).  
In developed countries such as the United States (US), underserved racial and 
ethnic minorities bear the highest burden of CVD (Mozaffarian et al., 2015). The US 
black population continues to be disproportionately affected by CVD related morbidity 
and mortality. For instance, the age-adjusted mortality attributable to CVD is 
approximately 34% higher in the black population compared to the overall US population 
(Mozaffarian et al., 2015). Although factors leading to these disparities are complex, 
barriers related to access of preventive and curative treatments are known to play a 
prominent role (Institute of Medicine, 2001). 
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The public health and socioeconomic ramifications of CVD, especially on the 
poor and underserved populations in both developed and developing countries require 
pragmatic and robust preventive initiatives. Feasible strategies that improve access and 
quality of CVD preventive treatments are necessary to address the burden of CVD in 
resource constrained settings. If well implemented, such strategies may promote 
cardiovascular health and economic progress of minority groups in developed countries, 
as well as the economically deprived populations in developing countries.  
Contemporary CVD management guidelines recommend absolute risk assessment 
as a clinically sound guide to CVD prevention and risk surveillance (Cooney, Dudina, & 
Graham, 2009; World Health Organization, 2007). Absolute CVD risk, also known as 
total or global risk, denotes the probability that an individual will develop CVD within a 
given time frame, depending on the combination and severity of the risk factors present 
(Jilcott et al., 2007). To facilitate absolute CVD risk assessment, dozens of algorithms 
have been developed to predict the likelihood that a particular constellation of risk factors 
will contribute to occurrence of CVD related morbidity or mortality over a specific 
period of time (Hayman, Helden, Chyun, & Braun, 2011; D. M. Lloyd-Jones, 2010a).  
For many years the available absolute CVD risk assessment algorithms were 
based on laboratory measures which are not readily available in resource constrained 
settings or for individuals with limited access to care (Beswick, Brindle, Fahey, & 
Ebrahim, 2008; Gaziano, Young, Fitzmaurice, Atwood, & Gaziano, 2008).  However, in 
recent years progress has been made in developing non-LB algorithms, a move that may 
be helpful for management of CVD in resource constrained settings.  
3 
 
A recent systematic review of literature reported that of the five published non-LB 
risk assessment algorithms for primary prevention of CVD, the non-LB Framingham 
algorithm had the best sensitivity and specificity ratios (Kariuki, Stuart-Shor, Leveille, & 
Hayman, 2013). In the high risk category (ten-year risk threshold of 20%) the algorithm 
had sensitivity/specificity ratios of 0.48/0.85 and 0.58/0.83 for men and women 
respectfully. These sensitivity/specificity ratios were comparable to the established LB 
Framingham algorithm (0.49/0.85 and 0.60/0.84) for men and women respectfully 
(D'Agostino RB et al., 2008).  
Despite the solid performance of the non-LB Framingham algorithm in its 
predominantly white (99.7%) derivation dataset, its performance and applicability in 
multiracial and black populations has not been tested. External validation is considered to 
be an essential process of testing the applicability of an algorithm to diverse populations 
with baseline characteristics which differ from those in the algorithm’s derivation dataset 
(Cooney et al., 2009). Without external validation, the suitability of the algorithm beyond 
the Framingham population remains uncertain.  
This study performed external validation of the non-LB Framingham algorithm in 
the multiracial Atherosclerotic Risk in Communities (ARIC) dataset (23% black). The 
external validation focused on evaluation of the algorithm’s ability to optimally stratify 
CVD risk and predict cardiovascular events in the multiracial population that forms the 
ARIC dataset. A sub-analysis focusing on the black participants enlisted in the ARIC 
study assessed the performance of the algorithm in a group that bears the highest burden 
of CVD, and more likely to reside in resource constrained or underserved settings in the 
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US. A subsequent cost effectiveness analysis evaluated the costs and benefits associated 
with using the algorithm in guiding prevention of CVD in the black participants enlisted 
in the ARIC study. Race was self-reported and individuals who report black race or white 
race will hereafter be referred to as “blacks” and “whites” respectively. 
Goals of the Study 
The main purpose of this study was to externally validate and cost the non-LB 
Framingham algorithm by testing four hypotheses to achieve three aims: - 
Specific aim 1: Assess the accuracy of the non-LB Framingham algorithm in 
stratifying risk and predicting CVD events a racially diverse population. 
Hypothesis 1: Non-LB Framingham algorithm will have adequate discrimination 
(Harrell’s C statistic greater than 0.75) and calibration (Hosmer-Lemeshow goodness of 
fit (χ 2) below 20 (p>0.05) in the multiracial ARIC dataset. 
Specific aim 2: Compare the performance of the non-LB Framingham algorithm 
in black versus white participants of the ARIC study. 
Hypothesis 2: There will be no significant difference in discrimination and 
calibration of the non-LB Framingham algorithm between the black and white 
participants of the ARIC study. 
Specific aim 3: Establish the cost feasibility of using the non-LB Framingham 
algorithm in guiding prevention of CVD among the black participants enlisted the ARIC 
study. 
Hypothesis 3:  A CVD prevention strategy guided by the non-LB Framingham 
algorithm will be more cost-effective compared with treating each elevated CVD risk 
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factor (diabetes and/or hypertension) independently in the black subset of the ARIC 
cohort. 
Hypothesis 4:  A CVD prevention strategy guided by the non-LB Framingham 
algorithm will be more cost-effective compared to a strategy guided by the LB 
Framingham algorithm in the black subset of the ARIC cohort.   
Significance and Innovation 
Validating and costing the non-LB Framingham algorithm was an important step 
in availing a risk assessment tool that could guide CVD prevention in resource 
constrained settings. The high representation of blacks in the ARIC cohort (23%) enabled 
adequate evaluation of the algorithm’s performance in this population that has the highest 
rates of CVD in the US.  
Defining Key terms  
In this study, the performance of the non-LB Framingham algorithm is assessed 
through external validation. External validation is the assessment of the performance of 
an algorithm in an external dataset. The external validation process is considered an 
essential step in assessing transportability of an algorithm to different populations 
because baseline survival and risk factors used in the test are not a perfect match for those 
in the algorithm’s derivation dataset (Cooney et al., 2009).The main approaches for 
measuring the performance include discrimination, and calibration. 
Discrimination is the ability of an algorithm to assign a higher risk to those who will 
develop the end point and a lower score to those who will not, and it is frequently 
measured using area under Receiver Operating Characteristic curve (AUROC) or 
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Harrell’s C statistic. AUROC or C statistic of 1 denotes perfect discrimination whereas 
0.5 equates to chance discrimination. Although the C statistic of CV risk assessment 
algorithms rarely exceeds 0.8, a valid algorithm should have a C statistic of 0.75 or 
higher (Cooney et al., 2009; May, Lawlor, Brindle, Patel, & Ebrahim, 2006). In addition, 
threshold discrimination operationalized by sensitivity and specificity is used to define 
low/high risk populations and treatment decisions are made in reference to this threshold 
(Cooney et al., 2009). 
Calibration is a measure of the agreement between the predicted outcomes and 
observed outcomes. It is frequently assessed using Hosmer-Lemeshow goodness of fit 
testing (χ 2). Goodness of fit (χ 2) values below 20 (lack of fit, p>0.05) are considered 
good fit (Cooney et al., 2009). 
Conceptual Framework 
The proposed study was guided by the Social Ecological and Chronic Care 
Models which are combined and adapted to provide an organizing structure for testing 
the validity and cost-effectiveness of the non-LB Framingham algorithm (see Figure 1).  
Various socioecological models were developed after the First World War to 
expand understanding of the dynamic relationship between various personal and 
environmental factors. In 1991 Dahlgren and whitehead published the Social Ecological 
Model to enhance understanding of policies and strategies to promote social equity in 
health. They contended that policies and strategies focusing on health equity should be 
based on a clear understanding of factors that threaten, promote or protect health 
(Dahlgren & Whitehead, 1991). 
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In the Social Ecological framework, the major factors that influence health are 
organized in hierarchical layers which include: macro-socioeconomic environment, living 
and work conditions, social and community networks, lifestyle choices, and 
genetical/constitutional factors (Dahlgren & Whitehead, 1991). The postulated influence 
of these interactive layers resonates with current knowledge on cardiovascular health 
trajectory which is known to be influenced by the interrelation between personal and 
environmental factors over an individual's lifetime (Hayman et al., 2011; Stuart-Shor, 
Berra, Kamau, & Kumanyika, 2012). 
 Personal factors, which include genetics and lifestyle, form the core of the model 
are affected by, and affect the social determinants of health which are espoused in the 
three outer layers of the Social Ecological model (see Figure 1).  The social determinants 
of health include life improving resources such as food supply, education, and social 
relationships, and their distribution across populations is well known to impact the health 
trajectory (Will, Keydron, Cynthia, Luis, & Zachary, 2011).  
The Chronic Care Model was developed by Dr. Edward Wagner and colleagues 
as part of the “Improving Chronic Illness Care initiative” supported by the Robert Wood 
Johnson Foundation (Bodenheimer, Wagner, & Grumbach, 2002). The initiative sought 
to develop innovations in primary care that would help close the quality gaps described in 
the 2001 Institute of Medicine report titled: Crossing the Quality Chasm: A New Health 
System for the 21st Century. In the report, the Institute of Medicine detailed many quality 
problems that caused a huge gap between current practices and attainable optimal chronic 
illness care in the US (Institute of Medicine, 2001). 
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To address these problems, the Chronic Care Model identifies the entire 
community, health care systems, and provider organizations as the three galaxies where 
chronic illness care occur (Bodenheimer et al., 2002). The three galaxies overlap and 
encompass six essential elements or pillars which may undermine or promote chronic 
illness care.  The six pillars include: community resources and policies, self-management 
support, health care organization, delivery system design, decision support, and clinical 
information systems (Barr et al., 2003; Bodenheimer et al., 2002). Improvements in these 
six essential and interrelated pillars are expected to produce reformed health care systems 
in which informed, activated patients interact with prepared, proactive health care 
providers (Bodenheimer et al., 2002).  
Although the six pillars of the Chronic Care Model are interrelated, only the 
decision support pillar is directly relevant to the objectives of this study as outlined in 
Figure 1. Therefore, the discussion of the other five pillars is beyond the scope of this 
study. The decision support pillar calls for integration of evidence based guidelines in 
routine protocols to help clinicians in making prudent clinical decisions in management 
chronic illness (Bodenheimer et al., 2002).  
Decision support is not intended to substitute individualized clinical judgement, 
but to support it by providing real time essential data on the patient or available evidence 
based interventions to the clinician. Optimal decision support tools may also promote 
self-management by making complex concepts more concrete and comprehensible to the 




The value of any tool used to support clinical decisions depends on the extent to 
which it is valid and applicable to the relevant clinical practice. Generally clinicians are 
more likely to use decision support tools that are not only valid, but also quick and easy 
to use (Cooney et al., 2009; Gaziano et al., 2008). The need for valid but simple, user 
friendly decision support tools is even more acute in resource constrained settings where 
non-physician health workers are increasingly being entrusted with traditionally 
physician responsibilities such as screening for and managing CVD. 
Absolute CVD risk assessment algorithms are considered as valid decision 
support tools appropriate for guiding CVD risk assessment and management. 
Consequently, the algorithms are currently used in many developed countries to support 
clinical decisions on CVD management by providing guidance on risk stratification and 
selection of treatment intensity (D. M. Lloyd-Jones, 2010b). In resource constrained 
settings, these algorithms are rarely used because they require laboratory measures that 
are usually inaccessible in these settings. Therefore, validating and costing the non-LB 
Framingham algorithm was an important step in availing a tool that would support 
implementation of evidence based guidelines in routine management of CVD.  
The absolute risk assessment algorithms use some covariates which are influenced 
by the dynamic relationship between personal and environmental factors included in the 
Social Ecological Model. Equipping healthcare providers with a decision support tool 
that enables them to have a comprehensive view of factors that threaten, promote or 
protect cardiovascular health is expected to make them well prepared and proactive in 
prevention and management of CVD. Individuals and populations served by such 
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proactive providers will have improved access to timely CVD risk assessment, increased 
risk awareness, and motivation to adherence. 
The Conceptual Theoretical and Empirical (CTE) structure 
The Social Ecological model’s proposition that a dynamic relationship between 
personal factors and the social determinants of health dictates the individual’s level of 
risk and subsequent development of disease forms the central concept of the framework. 
The chronic care model’s conceptualization of the importance of clinical decision support 
in shaping the dynamic relationship between personal factors and social determinants of 
health in favor of optimal cardiovascular health forms the middle range theory of the 
framework. Empirical indicators will include discrimination and calibration statistics 
quantifying the contribution of clinical decision support tool (non-LB Framingham CVD 
risk assessment algorithm) in detecting individual’s level of risk. Quantification of risk is 
expected to foster risk reduction discussion thereby producing proactive and well 






























In chapter 1, the concept of absolute CVD risk assessment and the role of valid 
and feasible risk assessment algorithms were introduced. The external validation process 
as well as the organizing framework for the study were also presented in the context of 
CVD. Chapter 2 will focus on the science behind these concepts and existing knowledge 
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Although the morbidity and mortality associated with CVD usually occur in 
middle and late adulthood, the main pathological pathway leading to CVD begins early in 
life and progresses cumulatively through adolescence and early adulthood (World Health 
Organization, 2007). This lifelong cumulative process is influenced by the interaction 
between constitutional (genetic) and lifestyle factors, with social determinants of health 
such as education and socioeconomic status as exemplified in the widely published social 
ecological model (Golden & Earp, 2012; Whitehead & Dahlgren, 1991). 
The insidious progression of CVD risk necessitates timely detection and initiation of 
preventive treatments. The major risk factors known to independently increase the risk of 
CVD include: cigarette smoking, high blood pressure, dyslipidemia, diabetes mellitus, 
and advancing age (Grundy, Pasternak, Greenland, Smith, & Fuster, 1999). Predisposing 
risk factors are known to aggravate the major CVD risk factors and include; obesity, 
physical inactivity, family history of premature CVD, ethnic characteristics, and 
psychosocial factors (Grundy et al., 1999). Co-occurrence or clustering of these risk 
factors is known to compound the effect of individual risk factors increasing the 
likelihood of developing CVD (World Health Organization, 2007)
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Absolute CVD risk assessment algorithms are recommended by contemporary 
CVD management guidelines to facilitate assessment of “total” or “global” risk. These 
algorithms take into consideration the clustering of risk factors in an individual to predict 
their likelihood of experiencing a CVD event within a given time frame, usually 10 years 
(Beswick et al., 2008). The foremost absolute risk assessment algorithms were derived 
from the Framingham Heart Study which was inaugurated in 1948 to investigate risk 
factors associated with development of CVD.  At the commencement of the study, the 
town of Framingham was an industrial trading center in North Eastern United States 
inhabited by white middle class families (Dawber, Meadors, & Moore, 1951). As a result, 
the cohort was 99.7% white. In 1971, descendants of the original cohort and their spouses 
were recruited to form the Framingham offspring cohort with an overarching goal of 
mapping the familial and genetic determinants of CVD. Similar protocols have been used 
in the examination of the original and offspring cohorts so as to enable combined 
analyses (Beswick et al., 2008). 
As part of the premier cardiovascular research study, the Framingham cohorts 
have been instrumental in identifying many CVD risk factors. The identified risk factors 
have been progressively included in the Framingham based algorithms, enabling 
significant improvements in risk discrimination and calibration (Beswick et al., 2008). 
High-density lipoprotein (HDL) cholesterol was identified and incorporated into 
Framingham risk assessment algorithms as an independent risk factor for CVD in 1968 
(Beswick et al., 2008). Traditionally, the Framingham algorithms have required 
14 
 
laboratory measures and were tailored to estimate the 10-year risk of developing coronary 
heart disease (Cooney et al., 2009).  
In an effort to simplify absolute CVD risk assessment, D'Agostino RB et al. (2008) 
developed a risk prediction model that demonstrated that Body Mass Index (BMI) could 
effectively substitute total and HDL cholesterol without compromising the robustness of 
the Framingham model. In the same study, the focus of risk assessment was broadened 
from a narrow focus on hard coronary events to a broader focus that entailed the full 
spectrum of CVD.  
The 2008 update of the Framingham model includes the simplified non-LB algorithm 
and the LB algorithm. Both the non-LB and LB algorithms were also modelled to predict 
general CVD events (coronary heart disease, cerebrovascular events, peripheral artery 
disease and heart failure). As a result of this broad focus, the absolute CVD risk 
estimated using the updated 2008 algorithms is significantly higher than when using 
earlier versions of Framingham model (D'Agostino RB et al., 2008).  
The predicted CVD risk (𝑝) in both the non-LB and LB algorithms is calculated using 
the general formulae: 𝑝 =  1 − S0(𝑡)
exp(∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−∑ =1 
𝑝
𝑖 ?̇?𝑖?̅?𝑖) where S0(𝑡) is baseline 
survival at follow-up time t (here t=12 years), ?̇?𝑖  is the estimated  regression coefficient, 
𝑋𝑖  is the log-transformed value of the ith  risk factor, (if continuous), ?̅?𝑖  is the 





The 2008 non-LB and LB Framingham algorithms use similar covariates (risk 
factors) except for substitution of BMI for cholesterol in the non-LB model as outlined in 
Table 1 (D'Agostino RB et al., 2008). This substitution had a benign effect on the model 
because both the non-LB and LB algorithms had comparable discrimination (C=0.749 vs. 
0.763 men & 0.785 vs. 0.793 women) and equally good calibration (χ 2 =13.61 vs. 13.48 
men & 10.24 vs. 7.79 women) in their derivation dataset respectively (D'Agostino RB et 
al., 2008). Although the Framingham cohort is more than 99% white, previous studies 
have suggested that Framingham risk prediction functions generally perform well in 
predicting coronary heart death and myocardial infarction among the US black 
population (D'Agostino RB, Grundy, Sullivan, Wilson, & CHD Risk Prediction Group, 
2001b). 
 In 2011, the 2008 LB Framingham model was tested in the multiracial third National 
Health and Nutrition Examination Survey (NHANES III) population, where it 
demonstrated optimal discrimination (C=0.776 men & 0.834 women); but calibration was 
not assessed due to lack of data on clinical end points (Pandya, Weinstein, & Gaziano, 
2011). The non-LB Framingham algorithm has been used to assess the effectiveness and 
impact of simulated national wide CVD screening strategies in Malaysia, but no 
published external validation studies have been found so far (Kariuki et al., 2013; 
Selvarajah et al., 2013). Therefore, validating and costing the non-LB algorithm in a 
multiracial population is an important step in availing a tool that could be instrumental in 
guiding prevention of CVD in resource constrained settings.
16 
 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The impact of CVD in resource constrained settings 
A striking similarity in the epidemiology of CVD in both developed and 
developing countries pertains to its impact on underserved populations. Although 
developed countries have strong health care systems, advanced medical technologies and 
abundance of resources, they are still dominated by high CVD mortality and morbidity 
(D. Lloyd-Jones et al., 2010). In 2011 the US spent over three hundred billion dollars to 
manage CVD. However, despite the staggering healthcare expenditure, CVD continues to 
take a lopsided toll on underserved minority groups especially the black population 
(Mozaffarian et al., 2015).  
In developing countries which are plagued by infectious diseases and 
underdeveloped fragile health care systems, CVD has significantly contributed to a 
protracted double burden of disease (S. Mendis et al., 2011). Despite lack of adequate 
resources to manage a full blown CVD epidemic, many developing countries are yet to 
implement feasible CVD prevention and surveillance initiatives. The inaction continues 
to expose masses of vulnerable populations to the dangers of cardiovascular events which 
are labor and resource intensive to manage.  
The burden and impact of CVD in the black US population 
According to the 2015 American Heart Association estimates, about half of all 
black adults in the US (48% women, 46% men) are affected by some form of CVD 
(Mozaffarian et al., 2015). In addition, US blacks bear a disproportionately high burden 
of CVD risk factors including obesity, diabetes, and hypertension. It is estimated that 
46% of women and 45% of men in the adult black population have high blood pressure 




high burden of CVD, blacks experience delays in CVD diagnosis and usually receive low 
quality of care leading to worse health outcomes (Bonow, Grant, & Jacobs, 2005).  
Although health disparities are complex and multi-factorial, the high burden of 
CVD in US blacks has been related to suboptimal access to the healthcare system, 
primary care providers, and preventive health services (Institute of Medicine, 2003). Lack 
of insurance coverage and geographic location has been identified as major access 
barriers to quality CVD preventive and curative treatments (Escarce, 2007). Overall, 
blacks have the second lowest health insurance coverage in every state of the union, 
coming only second to the Hispanics (Wilson, 2013).  With the escalating cost of health 
care, lack of insurance is a major deterrent to optimal health care access. 
Geographic location also plays an important role in limiting access to CVD 
preventive and curative treatments. Due to low education and high poverty levels, many 
US blacks reside in rural areas or inner cities. As a result of high crime rates and/or other 
environmental factors, health workers avoid working in inner cities leaving these 
populations without adequate health care access. The same trend is observed in most rural 
areas which are characterized by resource constrained health care systems and physical 
barriers such as distance and unavailability of transportation (Kamble & Boyd, 2008). 
These geographic limitations arguably make US blacks more likely to experience 
difficulties accessing health care, leading to disparate cardiovascular health outcomes.  
The US southern state of Mississippi has been cited as an example of how a 
geographical location can be a barrier to health care access. The state has highest 
proportion of rural-dwelling black women, and the highest heart disease death rate in the 




Mississippi have no physicians who specialize in heart disease (Kamble & Boyd, 2008). 
These geographic barriers and other challenges unique to resource constrained settings 
necessitates innovativeness to maximize each clinical encounter. 
Current policy initiatives aimed at reducing health care access barriers include 
subsidies to improve insurance coverage, and incentives to encourage health workers to 
provide services in marginalized rural or inner city communities (Brennan, Baker, & 
Metzler, 2008; National Rural Health Association, 2013). To reduce the burden of CVD 
in the US black population, these policy initiatives need to be supplemented by pragmatic 
strategies that would help reduce health care costs without compromising quality.  
Validating the non-LB Framingham algorithm in the black sample of ARIC 
cohort was an important step in availing a high quality CVD prevention tool that can be 
readily used in settings where laboratory measures are inaccessible due to location 
constraints or lack of insurance coverage. If validated, the algorithm will allow improved 
prediction of CVD events, enabling providers working in marginalized environments to 
better identify high risk individuals who require intensive preventive treatments. If used 
in combination with counseling, the validated algorithm may help to demonstrate a 
patient risk profile and indication for any proposed intervention (Shillinglaw, Viera, 
Edwards, Simpson, & Sheridan, 2012).  Although absolute CVD risk profile is in the 
context of the “average person” calculating the absolute CVD risk score provides a 
relatively concrete basis for engaging the patient on the abstract concept of risk. The 
ensuing patient-provider risk reduction discussion is likely to foster improved health 





Preventing CVD in resource constrained settings 
Integrating absolute CVD risk assessment into routine clinical assessment and 
population based surveys may foster a standardized opportunistic and proactive CVD risk 
surveillance and prevention in underserved populations. Availability of validated non-LB 
risk assessment algorithms will enable health care providers in resource constrained 
settings to initiate risk reduction discussion and interventions within one clinical visit. It 
has been estimated that an individual’s absolute risk score can be calculated within five to 
ten minutes using these algorithms because the only data required to estimate absolute 
risk include: age, BMI, systolic blood pressure, antihypertensive medication use, current 
smoking, and diabetes status (D'Agostino RB et al., 2008; Gaziano et al., 2008). This 
point of care utility may add great value in underserved populations which are difficult to 
follow.  
The proposed use of the non-LB Framingham algorithm, which was derived in a 
population that was 99.7% white, raises issues of applicability in black populations. 
Whereas poor performance of Framingham based algorithms has been reported in certain 
ethnicities (e.g. Hispanics), the models have performed reasonably well in predicting 
CVD in the US black population (Beswick et al., 2008).  
The adoption of algorithms developed in significantly different settings and 
populations is traditionally done under the assumption that the major risk factors for 
CVD are fairly similar around the world (Yusuf et al., 2004). The INTERHEART 
investigators delineated 9 major risk factors (smoking, lipids, hypertension, diabetes, 




psychosocial factors) which account for over 90% of the population attributable risk of 
acute myocardial infarction worldwide (Yusuf et al., 2004). 
Summary 
Validating and costing the non-LB Framingham algorithm could make an 
important contribution to the ongoing efforts to address the high burden of CVD in 
underserved communities especially the US black population. The challenges discussed 
in this review including the problem of limited access to healthcare due to location and 
lack of health insurance can be mitigated by availability of a valid and cost-effective risk 
assessment algorithm.  
Such an algorithm can be deployed at the point of service in real time, without 
need for follow-up visits to draw laboratory specimens or to review results. The time 
utility would make every visit in the resource constrained settings an opportunity to 
initiate risk reduction discussion, and to motivate adherence and self-management since 
the data required is readily collected during the office visit. To improve the effectiveness 
of CVD prevention while using the non-LB Framingham algorithm, individuals with 
borderline or indeterminate risk may then be further screened using the more resource 
intensive laboratory measures whenever feasible. 
Chapter 3 focuses on research design and methodology used in the external 





RESEARCH DESIGN AND METHODS 
Overview  
To address the specific aims of the project, a secondary data analysis was 
conducted using the ARIC dataset. The dataset is organized in four cohorts, three of 
which are predominantly or completely white (Forsyth County, NC; Suburbs of 
Minneapolis, MN; and Washington County, MD) while one cohort (Jackson, MS) is 
composed of black participants (ARIC Investigators, 1989). This diversity facilitated an 
adequately powered sub-analysis of the performance of the tool in the black sample.  
Data Source and Design  
The ARIC study is a prospective epidemiologic study with an overarching goal to 
investigate the etiology and natural history of atherosclerosis and its clinical sequelae, 
and examine the distribution of cardiovascular risk factors, medical care, and disease by 
race, sex, living location, and time. The study includes cohort and community 
surveillance components conducted in four ARIC field centers that include Forsyth 
County, NC; Jackson, MI; Minneapolis, MN and Washington County, MD. The Cohort 
Component of the study commenced in 1987, with each ARIC field center using driver 
license lists to randomly select about 4,000 individuals aged between 45-64 years from a 




A total of 15,792 individuals were recruited, but the ARIC dataset provided by the 
NHLBI included 15,053 adults who had no missing variables on the identification 
variable. Before the eligibility criteria was employed, the dataset included a total of 8,163 
women (54%) and 3,898 blacks (26%) aged 45-64 years. The sample was organized in 
four cohorts based on the ARIC field centers described earlier and all participants were 
examined at baseline between 1987 and 1989, followed by three more site-based 
examinations which ended in 1998. Yearly telephone follow-up interviews continue as a 
way to maintain contact with participants and to assess the health status of the cohort. 
Details of the examination procedures and criteria for the endpoints assessed have been 
reported elsewhere (ARIC Investigators, 1989). Table 1 summarizes sample 
characteristics, how essential risk factors relevant to this study were assessed, and CVD 
related endpoints monitored.   
This secondary data analysis focused on the first 12 years of follow-up after 
baseline examination in ARIC. Therefore, this study’s sample consists of study 
participants who attended baseline examination (1987-1989) and who at baseline were 
free of CVD, aged 45 to 64 years, and with no missing data on the variables of interest 
either at baseline or follow-up assessments in the next 12 years. The sample meeting 
these eligibility criteria includes 11,601 participants as described in Figure 2.  
The 12 years follow-up employed in this study matches the follow-up time used 
by (D'Agostino RB et al., 2008) when generating the non-LB and LB Framingham 
algorithms. This congruence of follow-up time will increase comparability of the 
performance of the algorithms in ARIC and Framingham datasets. The covariates 




status, smoking status, blood pressure, hypertension treatment and body mass index. The 
end points that are necessary to evaluate the calibration of the tool include the confirmed 
diagnosis of coronary artery disease, cerebrovascular disease, peripheral arterial disease 
and heart failure. Table 1 compares key aspects of the non-LB and LB Framingham 
algorithms and their derivation dataset, with the ARIC dataset in regard to design, 
sampling, assessments, data collected at baseline and the endpoints monitored. The cost-
effectiveness analysis focused on the black subset of the ARIC dataset who met the 
eligibility criteria described above. 
 
Figure 2: Flowchart of inclusion and exclusion criteria and monitored outcomes  
 









15,053  participants (26% Black, 54% Female) of the ARIC baseline exam 
(1987-1989) 
(A) Minneapolis, MN  
3,217 (100% White)
(B) Washington, MD  
2,893   (100% White)
(C) Jackson, MS  
2,381 (100% Black)  
(D) Forysth, NC    
3,110 (10% Black)
Ineligibile: 3,452 (23%)
*609 (18%) from Minneapolis, MN
*889 (26%) from Washington, MD
*1,052 (30%) from Jackson,MS
*799 (23%) from Forysth,NC
*103 (3%) cohort location missing
1,545 incident 
CVD events in 
the entire ARIC 
cohort (13.32%) 
401 incident 
CVD events in 
the black ARIC 
cohort (14.91%) 





In the ARIC cohort, the baseline examination commenced with participants 
giving informed consent. The baseline examination assessed CVD conditions and 
measured key athrogenic risk factors. Key elements of the interview included the 
assessment of angina (Rose Questionnaire), history of diabetes, transient ischemic attack, 
and peripheral arterial disease, smoking status and medications use. Positive history was 
verified by laboratory test results and/or in the medical records abstracted by nurse 
researchers (ARIC Investigators, 1989).  
Blood pressure was measured with the participant seated, with feet on the floor 
and arm at heart level, with three readings 5 minutes apart using random zero 
sphygmomanometer. The average of the second and third systolic blood pressure is 
entered into the model as a continuous variable. Anthropometric measurements were 
made with the participants wearing light-weight; non-constricting underwear, after 
emptying the bladder. Height and weight measurements were taken with the participant 
in light clothing and not wearing shoes. BMI was calculated as a function of height in 
meters and weight in kilograms, and was entered into the model as a continuous variable 
(ARIC Investigators, 1989).  
Diabetes was operationalized by two variables in the ARIC study. The DIABTS03 
variable defined diabetes as fasting glucose greater or equal to 126 mg/dL, and use of 
insulin or oral hypoglycemic medications, while the DIABTS02 variable applied a similar 
definition but used a fasting glucose level greater or equal to140mg/dL. Fasting glucose 
in both variables was measured during the scheduled baseline assessment, after at least 8 




entered as dichotomous variables, while antihypertensive medication use was determined 
through self-report and medication review as described in Table 1 (ARIC Investigators, 
1989). 
Similar protocols were used to measure covariates in the Framingham cohort, 
with the exception of diabetes whereby fasting glucose greater or equal to 126mg/dL was 
used as the threshold for diabetes in the Framingham offspring cohort, and greater or 
equal to 140mg/dL as the threshold for the original cohort (D'Agostino RB et al., 2008). 
In this analysis, we used DIABTS03 as the dichotomous variable indicating presence or 
absence of diabetes since it includes both thresholds used in the original and offspring 
cohorts of the Framingham study. Table 1 compares how selected sample characteristics, 
covariates and end points were assessed in the Framingham versus ARIC datasets.  
Follow-up Assessments  
All study participants were under continuous sentinel surveillance for the 
development of CVD events and death. The average follow-up response rate at year 12 
was 95.68%, will all cohorts having response rates greater than 93% (University of North 
Carolina at Chapel Hill, 2013). After the baseline examination, a telephone questionnaire 
was administered annually, including the Rose angina questionnaire (screens for angina) 
and items on general health and hospitalization. Events of interest during follow-up 
included hospitalized and non-hospitalized myocardial infarction, coronary heart disease 
death, angina pectoris, stroke, and intermittent claudication (ARIC Investigators, 1989). 
However, the events included in the secondary dataset provided by National Heart Lung 
and Blood Institute (NHLBI) included; coronary artery and cerebrovascular disease, atrial 




 In this analysis general CVD events include coronary heart and cerebrovascular 
disease, and heart failure. Atrial fibrillation and flutter were not included since they were 
not included in the Framingham cohort outcomes, while peripheral vascular disease 
outcomes were not availed in the ARIC dataset provided by the NHLBI (see Table 1). 
The cardiovascular events were ascertained through annual follow-up 
questionnaires, physical examinations at the study sites, communication with personal 
physicians and surveillance of medical records. Suspected new events were 
independently confirmed through review of medical charts by three experienced 
investigators, and neurological events were confirmed by a neurologist. Hospital records 
were abstracted twice independently by nurse abstractors to monitor CVD events; all 
substantive discrepancies were reconciled. Cardiac enzyme levels were recorded three 
times one day after the event, and two times for each of the next three days. The reviewed 
cardiac enzymes included: lactate dehydrogenase, lactate dehydrogenase subfractions, 
and creatinephosphokinase. Three serial electrocardiograms were reviewed, coded and 
interpreted at the University of Minnesota ECG Center using the full Minnesota code 
(ARIC Investigators, 1989).  
Underlying and contributory causes for all deaths of cohort members were also 
investigated to determine whether the cause was CVD. Where death occurred in a 
hospital, the hospital record was used, but if the decedent had died outside the hospital, 
family interviews, physician questionnaires, and coroner records were used (ARIC 
Investigators, 1989). 
The endpoints monitored in ARIC study follow-up closely correlate with the end 




included coronary events (coronary death, myocardial infarction, coronary insufficiency, 
and angina), cerebrovascular events (ischemic stroke, hemorrhagic stroke, and transient 
ischemic attack), peripheral artery disease (intermittent claudication), and heart 
failure.(D'Agostino RB et al., 2008) This congruence of protocols for assessing risk 
factors and endpoints (with exception of failure to include peripheral vascular disease in 
ARIC) enables rigorous external validation of the algorithm (see Table 1). Cost-
effectiveness measures are discussed separately in the analysis strategy under hypothesis 
3 and 4. 
Statistical Analyses 
The sex-specific non-LB Framingham algorithm was developed using sex-
specific Cox proportional-hazards regression models (Cox regression). The covariates 
included in the model, which were also measured in the ARIC dataset, entail; age, 
systolic blood pressure, antihypertensive medication use, current smoking, BMI, and 
diagnosis of diabetes mellitus (D'Agostino RB et al., 2008). To ensure coherence and 
rigor of the external validity analysis, the same regression model and covariates were 
used in the secondary analysis of the ARIC dataset since the necessary inputs were 
available in the dataset.   
Continuous variables (covariates) were transformed into natural logarithms to 
improve discrimination and calibration of the model and to minimize influence of 
extreme observations. Specific data on the exact days to incident CVD events since 
baseline examination, which are essential when using Cox regression, were included in 
the ARIC dataset. The incident CVD dates were ascertained through the rigorous follow-




communication with physicians since the participants had consented to these disclosures 
(ARIC Investigators, 1989).  
Cox regression allowed evaluation of the effect of various independent variables 
on the time at which a specified event occurs without making assumptions on the baseline 
hazard. Cox regression was used in the survival analysis after all the covariates included 
in the models met the proportionality of hazards assumption (Cleves, 2008). The 
assumption required; a) all continuous predictors such as systolic blood pressure to have 
a constant effect on survival across all analysis groups during the entire period of follow-
up; b) categorical predictors (e.g. smoking status) to have the same shape of hazard 
function within each analysis group during the entire period of follow-up.  
Analysis plan by study aims  
Specific aim 1: Assess the accuracy of the non-LB Framingham algorithm in 
stratifying risk and predicting CVD events in a racially diverse population. 
Hypothesis 1: Non-LB Framingham algorithm will have adequate discrimination 
(Harrell’s C statistic greater than 0.75) and calibration (Hosmer-Lemeshow goodness of 
fit (χ 2) below 20) in the multiracial ARIC dataset. 
This hypothesis was tested by evaluating the frozen sex-specific non-LB 
Framingham algorithm’s ability to: a) accurately stratify risk (discrimination) for persons 
who experienced a CVD event and those who did not, and b) predict CVD events 
(calibration), in the ARIC dataset. Discrimination (the ability of a risk prediction tool to 
assign a higher risk to those who will develop the end points of interest compared to 
those who will not) was measured using Harrell’s C statistic and AUROC curve. 




recommended in the literature (Cooney et al., 2009; May et al., 2006). In addition, 
sensitivity (proportion of individuals with CVD events who were predicted as high risk) 
and specificity (proportion of individuals without CVD events who are not predicted as 
high risk) of the tool was calculated using the roctab command in Stata©. 
Calibration of the mathematical models was assessed by measuring the 
concurrence between the predicted outcomes and observed outcomes using Hosmer-
Lemeshow goodness of fit statistic (χ 2). Kaplan-Meier survival analysis was used to 
obtain the observed incidence of CVD events, which was then be compared with the 
CVD events predicted by the non-LB Framingham algorithm. Kaplan-Meier method was 
preferred in this analysis because it allowed estimation of survival over time, even when 
some participants were censored or had varying lengths of follow-up. A Hosmer-
Lemeshow goodness of fit (χ 2) statistic below 20 was considered a good fit as 
recommended in literature (Cooney et al., 2009).  
The frozen Framingham model and algorithm was compared by one generated 
using ARIC data. In addition, re-calibration of the Framingham model using ARIC’s 
baseline survival and risk factor means was done and new recalibrated model and 
algorithm developed for comparability in discrimination and calibration (D'Agostino RB, 
Grundy, Sullivan, Wilson, & CHD Risk Prediction Group, 2001a). In this study, the 
frozen Framingham algorithm refers to the unaltered Framingham algorithms with 
baseline survival, regression coefficients and mean of risk factors as published by D 
’Agostino and colleagues (D'Agostino RB et al., 2008). 
Specific aim 2: Compare the performance of the non-LB Framingham algorithm 




Hypothesis 2: There will be no significant difference in discrimination and 
calibration of the non-LB Framingham algorithm between the black and white 
participants of the ARIC study. 
After validating the sex-specific non-LB Framingham algorithm in the entire 
ARIC cohort, a sub-analysis was conducted to assess the performance of the tool in the 
black and white cohorts. This analysis examined the ability of the tool to accurately 
predict CV risk in each racial subgroup stratified by sex.   The Statistical analyses 
approach described under hypothesis 1 were used to conduct the sub-analysis by race. 
Re-calibration was done by substituting Framingham baseline survival and risk factor 
means with race specific baseline survival and risk factor means in the ARIC dataset. All 
the non-LB models were compared with their LB counterparts using AUROC analysis 
and agreement using kappa statistic. The kappa-statistic is measure of inter-rater 
agreement, which is 0 when agreement is random and 1 when agreement is perfect.  
  Cost-effectiveness analysis 
Specific aim 3: Establish the feasibility of using the non-LB Framingham 
algorithm in guiding prevention of CVD among the black participants enlisted the ARIC 
study. 
Hypothesis 3:  A CVD prevention strategy guided by the non-LB Framingham 
algorithm will be more cost-effective compared with treating each elevated CVD risk 





Hypothesis 4:  A CVD prevention strategy guided by the non-LB Framingham 
algorithm will be more cost-effective compared with a strategy guided by the LB 
Framingham algorithm in the black subset of the ARIC cohort.   
This analysis compared the cost-effectiveness of a CVD prevention strategy 
guided by absolute CVD risk estimates, calculated using the non-LB and LB 
Framingham algorithms, visa-vis an approach based on treating each elevated CVD risk 
factor (diabetes and/or hypertension) independently in the black subset of the ARIC 
cohort.  
Although there are seven major risk factors for CVD that are modifiable, only two 
were included in costing the approach based on treating individual CVD risk factors. 
Hypertension and diabetes were selected due to their strong association with CVD and 
their significance in the global public health agenda.  Hypertension is the leading cause of 
CVD worldwide, and diabetes is known to double the risk of CVD events (S. Mendis et 
al., 2011). 
The thresholds for initiating therapy and treatment modalities in the individual 
risk factors approach e based on recommendations from the American Society of 
Hypertension and International Society of Hypertension (ASH-ISH) guidelines for 
management of hypertension, and the International Diabetes Federation (IDF) guidelines 
for management of diabetes (IDF Clinical Guidelines Task Force, 2006; Weber et al., 
2014). The guidelines were selected for costing due to their primary focus on either 
diabetes or hypertension, and their international applicability. The essential components 
of these guidelines relevant to this analysis are discussed below and summarized in 




According to the ASH-ISH guidelines, hypertension is defined as systolic blood 
pressure greater or equal to 140 mmHg or diastolic blood pressure greater or equal to 90 
mmHg or both. The guidelines recommend timing and tailoring the intensity of treatment 
based on the stage of hypertension.  Stage 1 hypertension is defined as systolic blood 
pressure below 160 or diastolic blood pressure below 100, while stage 2 hypertension 
denotes blood pressures above these thresholds. Monotherapy with a calcium channel 
blocker (e.g. Amlodipine) or a thiazide diuretic (e.g. Hydrochlorothiazide) is 
recommended for blacks with stage 1 hypertension irrespective of their diabetes status, 
while addition of a second agent (angiotensin-converting enzyme (ACE) inhibitor in 
diabetes) is recommended in stage 2 hypertension as outlined in Figure 3. 
 In resource constrained settings, the guidelines recommend use of lifestyle 
modification for up to one year before starting drug therapy in stage 1 hypertension when 
no other CVD risk factors are present. All treatment modalities are focused on attaining 
targets below the diagnostic threshold but no explicit follow-up regimen is provided by 
the ASH-ISH guidelines (Weber et al., 2014).   
The IDF guidelines defines diabetes as fasting blood sugar greater than 7 mmol/l 
(126mg/dL) or random blood sugar above 11.1mmol/l (200mg/dL). Treatment options 
are graded from first-line to fourth-line therapy depending on attainment of glucose 
control targets. First-line therapy includes monotherapy with a biguanide (e.g.  
Metformin) or an equivalent agent, while second-line therapy adds a sulfonylurea (e.g. 
Glipizide) or an equivalent agent as summarized in Figure 3.  Addition of a third agent, 
such as a-glucosidase inhibitor, or starting insulin treatment constitutes third-line therapy. 




initiated alongside oral hypoglycemic agents as part of fourth-line therapy. The 
guidelines also recommend use of statins (based on lipid levels) to reduce risk of CVD 
events and periodic monitoring of glycated hemoglobin (HbA1C) as part of a 
comprehensive management program (IDF Clinical Guidelines Task Force, 2006). A 
follow-up regimen is not explicitly stipulated. Figure 3 outlines risk stratification and the 
basic preventive interventions prescribed by the approach guided by treating individual 
CVD risk factors.  












CVD prevention strategy based on treating diabetes and hypertension to target goals adapted from ASH-
ISH and IDF guidelines (IDF Clinical Guidelines Task Force, 2006; Weber et al., 2014) 
The absolute risk approach to CVD prevention is recommended by major CVD 
management guidelines based on the premise that whereas individual risk factors 
independently increase the likelihood of CVD events, clustering of multiple risk factors is 
known to compound the CVD risk (Beswick et al., 2008). Guidelines adopting the 
absolute risk approach to CVD prevention tailor the choice and intensity of recommended 
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treatments based on absolute CVD risk scores calculated using CVD risk assessment 
algorithms, such as the non-LB Framingham algorithm externally validated in this study.  
The 2007 CVD prevention guidelines by the WHO were selected as the basis for 
costing interventions associated with the absolute risk approach due to their congruence 
with Framingham algorithms and relevance to primary prevention of CVD. Interventions 
recommended by the WHO guidelines (see Table 2) are based on absolute risk scores for 
general CVD events including coronary heart disease, peripheral vascular disease and 
cerebral vascular disease (World Health Organization, 2007). Both the non-LB and LB 
Framingham algorithms validated in this study were developed to predict these general 
CVD events, these are broader outcomes than the hard coronary events predicted by 
earlier versions of Framingham (D'Agostino RB et al., 2008). Currently there are no 
feasible alternatives to the WHO guidelines since the American Heart Association CVD 
prevention guidelines are dated (published in 2002) and limited by their narrow focus on 
hard coronary events (Pearson et al., 2002).  
The WHO CVD prevention guidelines organize their recommended preventive 
interventions in four categories based on absolute CVD risk scores as follows; low risk 
(>10%), moderate risk (10% to 20%), high risk (20% to 30%) and very high risk >30%. 
Table 2 outlines the four risk categories and the treatment options recommended for each 
(World Health Organization, 2007). According to these guidelines, an individual with an 
absolute risk score >30% is: a) scheduled for follow-up visits at least every 6 months, b) 
started on antihypertensive therapy (if blood pressure is greater or equal to 
130/80mmHg), c) started on a statin, d) put on glucose lowering therapy (if fasting blood 




Table 2: WHO choice & intensity of CVD prevention strategy guided by absolute CVD risk 
 
CVD prevention strategy based absolute risk score, adapted from the WHO CVD prevention guidelines (World 
Health Organization, 2007). 
Key: TC (total cholesterol); FBS (fasting blood sugars) 
a Smoking cessation and lifestyle management recommended across risk profiles 
b Abstaining or reducing alcohol intake to <3units per day recommended across risk profiles 
c First line antihypertensive therapy includes: thiazide-like diuretic, ACE inhibitor, calcium channel blocker 
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Monitor risk profile 
every 3-6 monthsa,b
Treat BP≥160/100 with 
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Monitor risk profile 
every 6-12 monthsa,b
Treat BP ≥160/100 
with recommended 
drugsc
Lifestyle mx for  
persistent BP≥140/90 
reassess annually
Lipid lowering diet; 
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Case example: individual vs absolute CVD risk approach 
The differences between the individual risk factors approach and the absolute risk 
approach to CVD prevention are evident in the treatment modalities recommended in 
Figure 3 and Table 2 for each strategy respectively. A case example is Mr. Q, a 57 years 
old male, who is a smoker with no history of diabetes or hypertension.  He presents with 
a blood pressure of 138/88 mmHg, fasting blood sugar of 6 mmol/l (108mg/dL), HDL of 
1.16 mmol/l (45mg/dL), total cholesterol of 5.84 mmol/l (226 mg/dL) and a BMI of 26.  
If the individual risk factors approach outlined in Figure 3 was used to manage 
Mr. Q, only lifestyle modification, with emphasis on smoking cessation, would be 
recommended since he does not meet the hypertension threshold specified by the ASH-
ISH guidelines or the threshold for diabetes recommended by the IDF guidelines.  
If the absolute risk approach was used to manage Mr. Q, he would have an 
absolute CVD risk score of 30.4% and 30.1% according to the online interactive non-LB 
and LB Framingham absolute CVD risk calculators respectively (D’Agostino & Pencina, 
2016). These absolute CVD risk calculators use the general formulae for predicting CVD 
events outlined in the literature review section. The general formulae combine sundry 
CVD risk factors to calculate the probability of a CVD event occurring within a 
maximum time frame of 12 years.  
Mr. Q absolute CVD risk score is very high despite apparently normal or near 
normal individual risk factors because the score appreciates the additive nature of subtle 
elevations in CVD risk factors (e.g. blood pressure, BMI and total cholesterol). 
Consequently, in addition to lifestyle modification, the absolute risk approach based on 




the relevant interventions under the “very high risk category” (>30%) in Table 2. The 
relevant interventions for Mr. Q would include: follow-up visits at least every 6 months, 
antihypertensive therapy (since BP>130/80mmHg), statin therapy, and low dose aspirin. 
Absolute versus individual risk decision model 
 In order to fully appreciate the differences between the individual risk factors and 
absolute risk approaches to CVD prevention, the black cohort in ARIC was stratified by 
the type of screening algorithm used in the preventive approach. The different categories 
for each CVD prevention approach are summarized in Figure 4.1 and detailed below. 
 When the individual CVD risk factor approach was employed (lower arm in 
Figure 4.1), the black cohort free of CVD at baseline was stratified into high and low 
CVD risk categories depending on presence or absence of diabetes and/or hypertension. 
The true and false high risk categories were both prescribed the intensive preventive 
interventions outlined in Figure 3, while the true and false negatives were prescribed 
lifestyle management. The false positives ended up receiving unnecessary intensive 
treatment, while the false negatives missed essential treatment culminating in CVD 
events. In the simulated analysis, a high number of false positives were expected to 
increase level II expenses, while a high number of false negatives would increase level III 
expenses due to treatment and rehabilitative costs associated with CVD events that occur 
as a result of missing preventive interventions. 
When the absolute CVD risk approach was employed guided by either the non-
LB or LB Framingham algorithm, the black cohort free of CVD at baseline was stratified 
into four CVD risk categories based on their absolute risk score. When a specific risk 




sensitivity/specificity analysis, individuals below the threshold were assumed to be low 
risk, while those above the threshold were considered high risk and put under the 
treatments prescribed for their respective category.  
For instance, if the moderate risk category (10-20%) in Figure 4.1 was set as the 
treatment threshold, the sample with absolute risk score below 10% would be exempted 
from treatment, while individuals in other risk categories would receive the appropriate 
therapy based on their risk sore as outlined in Table 2. As a result, the false positives 
receive unnecessary treatments and increase level II expenses, while the false negatives 
miss essential preventive treatments culminating in CVD events which incur level III 
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  Cost-effectiveness framework 
The incremental cost effectiveness tested under hypothesis 3 and 4 was done 
under the framework of the cost-effectiveness model below adapted from the methods 
described by Drummond for evaluating incremental costs and effects of a program 
(Drummond & Drummond, 2005).  To adapt the equation for hypothesis 4, the individual 
risk factors (r) approach was substituted with the LB Framingham (l) approach). 












𝑡   
ICER model Key:  
 ICER = incremental cost-effectiveness ratio 
 TCa – r = the discounted difference between the total costs incurred in 12 years to 
manage CVD in the absolute (a) versus the individual risk factors (r) approach. 
 Ea – r = the discounted difference between true positives predicted in the absolute (a) vs. 
the individual risk factors (r) approach. 
 CRxajt, CRxrjt = the discounted cost of preventive interventions (see Table 2) prescribed to 
the j-th risk group predicted by absolute (a) versus by individual risk factors (r) approach 
in year t (same for CRxrjt, use Figure 3). 
 CUSEajt, CUSErjt = the discounted cost of treating 3 major CVD events occurring (false 
negatives in Figure 4.1) in the j-th risk group associated with absolute (a) vs individual 
risk factors (r) approach in year t (same for CUSErjt) 
 CVDajt-CVDrjt = the discounted difference between true positives predicted in the j-th 
absolute or individual risk factors group in year t.   
 d = 3% discount rate as recommended by the US Panel on Cost-Effectiveness in Health 
and Medicine (Weinstein, Siegel, Gold, Kamlet, & Russell, 1996). 
Each preventive approach was costed on three levels as outlined in Figure 4.1. Level I 
expenses includes screening costs, level II expenses included the cost of preventive 
interventions prescribed in Table 2 for the absolute risk approach, and Figure 3 for the 
individual risk factors approach, while level III expenses included the cost of treating 
CVD events that occurred in the false negative group. Outcomes in this analysis included 
three CVD events (fatal and non-fatal CHD, heart failure, and stroke) expected to be 




level I and II expenses constituted CRx, while level III expenses were represented by 
CUSE in the ICER model.  All costs and outcomes were discounted at the rate of 3% as 
recommended by the US Panel on Cost-effectiveness in health and medicine (Weinstein 
et al., 1996).  
Discounting refers to the practice of weighting future gains and losses less heavily 
than those that occur in the present. The concept is based on the premise that a dollar or a 
life is worth more today that it would be in the future (Smith & Gravelle, 2001). In this 
analysis, discounting is used to estimate the present value of future costs and CVD events 
associated with each of the three CVD prevention programs. 
  Interpreting the ICER 
The incremental cost-effectiveness ratio was interpreted using a cost-effectiveness 
plane adapted from Drummond (Drummond & Drummond, 2005). In this analysis, the 
existing programs were considered to be the individual risk factors and LB absolute risk 
approaches to CVD prevention, while the new program was considered to be the non-LB 
absolute risk approach.  In the plane outlined in Figure 4.2, an ideal ICER ratio would be 
a more effective and less costly new program as depicted in the lower right quadrant. The 
ratio could also be acceptable if the new CVD prevention program is slightly less 
effective but way less costly (see left lower quadrant), or more expensive but highly 
effective compared to the existing programs (see right upper quadrant). An expensive but 
less effective program is unacceptable under all circumstances.  At origin, the new 





































The external validation described in this chapter entails evaluation of 
mathematical performance and applicability of the Framingham non-LB algorithms in the 
ARIC dataset. Mathematical performance is evaluated by reproducing the underlying 
Framingham mathematical models in ARIC and comparing their regression coefficients, 
discrimination and calibration with those derived in the Framingham dataset. 
Applicability of the Framingham algorithms in ARIC is evaluated by comparing the 
AUROC’s and sensitivity/specificity ratios of CVD risk stratification based on the 
published Framingham algorithms versus other models generated in the ARIC dataset. 
This chapter is organized in five parts to address; a) description of the ARIC 
sample baseline characteristics and incident CVD events, b) mathematical performance 
of the Framingham models in ARIC dataset, c) performance of the Framingham 
algorithms in the ARIC sample, d) sensitivity/specificity analysis of the algorithms 
applied to predict risk in the ARIC sample, and e) simulated cost-effectiveness analysis 




a)  Sample description 
This section describes the baseline characteristics of the eligible and ineligible 
sample based on the criteria discussed in the methods section, and the observed 
incidence of CVD events within the 12 years of follow stratified by sex and race.  
Sample characteristics 
The ARIC dataset provided by the NHLBI consisted 15,053 participants who 
completed the ARIC baseline exam between 1987 and 1989. Twenty-six percent of these 
participants were black and 55% were female. When the eligibility criteria described in 
the methods section were applied, 23% (3,452) of the original ARIC cohort was 
excluded. Therefore, the sample in this study includes 11,601 participants (23% black, 
55% female).  
The baseline characteristics of the eligible and ineligible sample are described in 
Table 3.1. Overall, 82% of those excluded had CVD at baseline examination. When the 
eligible sample was stratified by sex, men had a higher profile of CVD risk factors 
(diabetes, hypertension, smoking, HDL and total cholesterol) compared to women except 













Table 3.1: Baseline characteristics stratified by eligibility criteria 
 Eligible Ineligible 
 
P (95% CI) 
N 11601 3452  
Male (n, %) 5246 (45.22) 1541 (46.01) 0.417 
white (%) 8911 (76.81) 2141 (63.93) 0.000 
Age (mean, sd) 53.91 (5.74) 55.43 (5.69) 0.000 
Diabetes (n, %) 1152 (9.93) 658 (20.48) 0.000 
Current smoker (n, %) 2970 (25.60) 990 (29.69) 0.000 
BMI (mean, sd) 27.39 (5.14) 28.84 (5.96) 0.000 
SBP (mean, sd) 120.27 (17.99) 125.35 (21.90) 0.000 
Hypertension (n, %) 3,866 (33.32) 2116 (64.28) 0.000 
BP treatment (n, %) 2775 (23.92) 1858 (55.61) 0.000 
HDL (mean, sd) 52.15 (17.08) 48.92 (16.93) 0.000 
Total chol (mean, sd) 214.21 (41.05) 218.19 (45.36) 0.000 
Baseline CVD (n, %) 0 (0) 2801 (81.52) 0.000 
Baseline characteristics recorded at the baseline exam for entire ARIC cohort between 1987 and 1989 
Data presented as mean/SD for continuous variables and as frequencies (%) for categorical variables  

















N 4758 1597   4153 1093  
Diabetes ( %) 6.85 18.79 0.000  8.72 15 0.000 
Current smoker (%) 24.88 23.67 0.329  24.01 37.60 0.000 
BMI (mean, sd) 26.3 (5.2) 30.6 (6.3) 0.000  27.3 (3.9) 27.5 (4.9) 0.213 
SBP (mean, sd) 116.4 (17.4) 126.5 (19.5) 0.000  120 (15.8) 129 (20.1) 0.000 
Hypertension (%) 27.87 53.73 0.000    26.99 51.33 0.000 
BP treatment (%) 21.21 42.08 0.000  18.28 30.65 0.000 
HDL (mean, sd) 58 (17) 58.3 (17.3) 0.525  43.2 (12.4) 51.3 (17.2) 0.000 
Total chol (mean, sd) 217.4 (41.4) 216.5 (44.4) 0.464  210.3 (38) 211.6 (43.1) 0.319 
Age (mean, sd) 53.8 (5.7) 53.1 (5.8) 0.000  54.4 (5.7) 53.5 (6) 0.000 
Intermediate educ. (%) 51.16 29.59 0.000  39.43 26.72 0.000 
Advanced educ. (%) 33.85 32.79 0.000  44.61 31.22 0.000 
Baseline characteristics recorded at the baseline exam for entire ARIC cohort between 1987 and 1989 
Data presented as mean/SD for continuous variables and as frequencies (%) for categorical variables  








Incident CVD during 12 years of follow-up 
During the 12 years of follow-up included in this analysis 1,545 new cases of 
CVD occurred in the eligible ARIC cohort comprised of 11,601 individuals. This 
translated into 11.1 incident CVD cases per 1000 persons-years.  Stratified by sex and 
race, the incidence rate among white versus black women was 6.5 versus 10.2 cases per 
1000 person-years respectively, and 15.5 versus 15.6 cases per 1000 person-years among 
white versus black men respectively.  
white and black men had the highest incidence rate of CHD (12.1 and 9.0 cases 
per 1000 person-years respectively), while black and white women had the lowest 
incidence (4.3 and 3.7 per 1000 person-years respectively). The incidence of heart failure 
was highest among black women and men (5.4 and 5.2 cases per 1000 person-years 
respectively), while white men and women had the lowest incidence (4.6 and 2.7 cases 
per 1000 person-years respectively). The incidence of stroke was highest among black 
men and women (4.7 and 3.9 case per 1000 person-years respectively). White men and 
women incidence of Stroke was low at 2.4 and 1.4 cases per 1000 person-years 
respectively. Figure 5 shows the incidence rate of general and cause specific CVD events 













Figure 5: General & cause specific CVD incidence rate in ARIC stratified by sex & race 
 
 
The incidence proportion of CVD during the 12 years of follow-up was 13.3% in 
the entire ARIC cohort. Stratified by sex and race, the incidence proportion was 7.8% 
versus 12.3% among white versus black women respectively (p=0.000), and 18.6% 
versus 18.8% among white and black men respectively (p=0.900). Figures 6 depict the 
incidence proportion of general and cause specific CVD during the 12 years of follow-up 





















































Data source: ARIC 1987-1999











Figure 6: General & case specific CVD incidence proportion in ARIC stratified 
by sex & race 
 
    
b) Mathematical models’ performance 
In this section, two mathematical models, namely unadjusted and adjusted 
Framingham models, were developed and their mathematical performance compared to 
the published (frozen) Framingham model. The unadjusted model was generated by 
running a Cox regression model that included only the covariates used to derive the 
published Framingham algorithms, while the adjusted model included additional 
covariates postulated to improve the discrimination and calibration of the published 
Framingham models. The mathematical model performance was evaluated using the 































Data source: ARIC 1987-1999









the regression coefficients generated in the unadjusted model were compared to the 
published (frozen) Framingham coefficients to compare the effect size of each covariate 
in the Framingham versus ARIC cohorts.  
 Both the unadjusted and adjusted models met the proportional hazards assumption 
(global test >0.05) and did not indicate presence of multicollinearity among the 
covariates. To compare the effect of each covariate in the Framingham versus ARIC 
cohorts, a statistical test of the difference in their respective regression coefficients (β) 
was done using the z-score formula: 𝑧 = (𝑏1 − 𝑏2) √(𝑠𝑒𝑏12⁄ + 𝑠𝑒𝑏22) , where 𝑏1 and 
𝑏2 are the unstandardized regression coefficients (β), while 𝑠𝑒𝑏1 and 𝑠𝑒𝑏2 are the standard 
errors of the regression coefficients (Paternoster, Brame, Mazerolle, & Piquero, 1998). 
Regression coefficients with similar effects across cohorts are expected to have a z score 
in the interval -1.96 and +1.96. A positive z means that the regression coefficient in 
ARIC was greater than Framingham and vice versa. 
  The unadjusted non-LB Framingham models 
The Cox regression analysis including the non-LB covariates (sex, age, smoking 
status, diabetes status, antihypertensive medication use, systolic blood pressure and BMI) 
satisfied the proportional hazards assumption with a global test of p=0.2384 among 
women and p=0.2873 among men. All the covariates included in the unadjusted non-LB 
Framingham model were statistically significant (p<0.05) in both sexes and in the white 
cohort, but BMI was not significant in the black cohort (p=0.071 for women and 0.128 
for men). In addition, untreated systolic blood pressure was not statistically significant 
among black men (p=0.065). Table 4 describes the regression coefficients for the 




Stratified by sex only, the regression coefficients generated in the unadjusted non-
LB Framingham model were similar to the frozen non-LB Framingham regression 
coefficients, except for the smoking covariate among men and women, and the diabetes 
covariate among men. The effect of smoking was higher among women (z score of 3.28) 
but lower among men (z score of -2.842) in ARIC compared to the Framingham cohort. 
The effect of diabetes was higher among men (z score of 2.188) but similar among 
women in ARIC compared to the Framingham cohort.  
Stratified by sex and race, the regression coefficients for all strata were similar to 
the frozen non-LB Framingham regression coefficients, except for the smoking and 
diabetes coefficients which were different in the white cohort. Smoking had a higher 
effect among white women (z score of 3.327) and a lower effect among white men (z score of 
-2.637) in ARIC compared to the Framingham cohort. Diabetes had a higher effect among 
white men (z score of 2.174) but similar effect among white women in ARIC compared 
to the Framingham cohort.  Table 4 shows the regression coefficients for the unadjusted 












Table 4: Regression beta coefficients of the unadjusted non-LB Framingham in ARIC 




Female coefficients stratified by race 
 



















z = 3.28† 
1.106*** 
[0.108] 






z = -2.842† 
0.411*** 
[0.0826] 
z = -2.637† 
0.501*** 
[0.145] 





z = 1.65 
1.073*** 
[0.136] 
z = 1.467 
1.044*** 
[0.154] 
z = 1.25 
0.831*** 
[0.0814] 
z = 2.188† 
0.848*** 
[0.0948] 
z = 2.174† 
0.831*** 
[0.161] 
z = 1.537 




z = 0.788 
3.333*** 
[0.545] 






z = -0.164 
2.881*** 
[0.372] 
z = -0.540 
3.330*** 
[0.654] 
z = 0.316 




z = 0.828 
0.797** 
[0.284] 
z = 0.726 
0.668 γ 
[0.370] 






z = 0.180 
0.631 
[0.415] 






   z = -1.701 
1.808*** 
[0.435] 
z = -1.786 
2.158*** 
[0.633] 
z = -0.902 
1.499*** 
[0.270] 
z = -0.897 
1.790*** 
[0.323] 
 z = -0.151 
1.018γ 
 [0.551] 
z = -1.341 





z = 0.425 
3.054*** 
[0.600] 
z = 0.247 
3.033*** 
[0.531] 
z = 0.235 
1.834*** 
[0.399] 
z = -0.188 
1.719*** 
[0.497] 
z = -0.361 
2.246** 
[0.693] 
z = 0.425 
* p<0.05, ** p<0.01, *** p<0.001 γ p<0.1 
Standard errors in brackets 
z = score comparing published non-LB Framingham coefficients with those generated in ARIC using the 
formulae 𝑓(𝑧) = (𝑏1 − 𝑏2) √(𝑠𝑒𝑏12⁄ + 𝑠𝑒𝑏22); † denotes z score >1.96 or < -1.96. Positive z means the 
regression coefficient in ARIC was greater than Framingham & vice versa 
 
 
In regards to risk stratification and congruence between predicted and observed 
CVD events, the unadjusted non-LB Framingham model had a higher discrimination 
statistic and better calibration among women compared to men. However, no significant 
differences in discrimination were observed between blacks and whites within their 
respective sexes. Women had a C statistic of 0.75 (95% confidence interval [CI], 0.73-
0.77) compared to men’s 0.67 (95% CI, 0.65-0.68). When stratified by sex and race, 
white women had a C statistic of 0.746 (95% CI, 0.72-0.77) compared to black women’s 




0.68) compared to black men’s 0.683 (95% CI, 0.65-0.72). The published (frozen) non 
LB Framingham model had a C statistic of 0.785 (95% CI, 0.764-0.806) for women and 
0.749 (95% CI, 0.731-0.767) for men.  
Calibration was good (p>0.05) among women but poor among men with Hosmer-
Lemeshow goodness of fit (df 8) χ 2= 14.2 (p=0.1154) versus 25.8 (p=0.0022) 
respectively as depicted in Figure 7 and 8 below. When stratified by sex and race, 
calibration was good among all ARIC cohorts except white men with Hosmer-Lemeshow 
goodness of fit (df 8) χ 2= 19.6 (p=0.0208). The published Framingham model had a 
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 10.24 for women (p=0.33) and 13.61 
(p=0.14) for men. 
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Figure 8: Calibration- unadjusted non-LB based Framingham men specific model 
  
  The unadjusted LB Framingham models 
The Cox regression analysis including the LB covariates (sex, age, smoking 
status, diabetes status, antihypertensive medication use, systolic blood pressure total 
cholesterol and HDL) also satisfied the proportional hazards assumption over the 
duration of follow-up with a global test of p=0.2999 among women and p=0.4111 among 
men. All the covariates included in the unadjusted LB Framingham model were 
statistically significant (p<0.05) in both sexes and in the white cohort, but total 
cholesterol was not statistically significant in the black cohort (p=0.356 for women and 
0.867 for men). Table 5 presents the regression coefficients for the unadjusted LB 
Framingham model, stratified by sex and race. 
When stratified by sex, all the regression coefficients generated in the unadjusted 
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coefficients, except for the smoking status among men and women. Smoking had a 
higher effect among women (z score of 2.946) but a lower effect among men (z score of -
2.720) in ARIC compared to the Framingham cohort. Table 5 below describes the 
regression coefficients for the unadjusted LB Framingham model and the associated z 
scores stratified by sex. 
Table 5: Regression beta coefficients of the unadjusted LB Framingham in ARIC and z 




Female coefficients stratified by 
race 
 






















0.918***        
[0.0879] 
z= 2.946†          




0.370***    
[0.0700] 
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0.793***    
[0.0808] 
z= 1.609          
0.803*** 
[0.0944]          
0.803*** 
[0.159]   









2.966***        
[0.320]  
z= -0.24          
2.851*** 
[0.371]          
3.337*** 
[0.655] 













1.254***       
[0.202]          
0.0581   
[0.346]    
Log of HDL 
-0.987***  
[0.146] 




[0.267]    
-0.896***  
[0.112]    


























[0.386]   
z= 0.741         
2.911*** 
[0.593]                  
3.065*** 








* p<0.05, ** p<0.01, *** p<0.001 
Standard errors in brackets 
z = score comparing published non-LB Framingham coefficients with those generated in ARIC using the 
formulae 𝑓(𝑧) = (𝑏1 − 𝑏2) √(𝑠𝑒𝑏12⁄ + 𝑠𝑒𝑏22); † denotes z score >1.96 or < -1.96. Positive z means the 





The unadjusted LB Framingham model also had a higher discrimination statistic 
and better calibration among women compared to men, with no significant differences in 
discrimination between blacks and whites within their respective sexes. Women had a C 
statistic of 0.76 (95% CI, 0.74-0.78) compared to men’s 0.68 (95% CI, 0.67-0.70). When 
stratified by sex and race, white women had a C statistic of 0.754 (95% CI, 0.73-0.78) 
compared to black women’s 0.750 (95% CI, 0.72-0.78), while white men had a C statistic 
of 0.685 (95% CI, 0.67-0.70) compared to black men’s 0.69 (95% CI, 0.65-0.73).  The 
published LB Framingham model had a C statistic of 0.793 (95% CI, 0.772-0.814) in 
women and 0.763 (95% CI, 0.746-0.780) for men.    
 Calibration was good (p>0.05) among women but poor among men with 
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 10.5 (p=0.3084) versus 21.8 (p=0.0095) 
respectively as depicted in Figure 9 and 10. When stratified by sex and race, calibration 
was good among all ARIC cohorts except white men with Hosmer-Lemeshow goodness 
of fit (df 8) χ 2= 25.5 (p=0.0024). The published LB Framingham model had a Hosmer-
























Figure 10: Calibration- unadjusted LB Framingham men specific model 
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  The adjusted non-LB model 
In a bid to improve discrimination and calibration, additional variables known to 
be CVD risk factors were sequentially added to the covariates included in the published 
non-LB Framingham model, and their statistical significance evaluated. The additional 
variables included waist hip ratio and family history of premature CHD.  A new model 
(adjusted non-LB model) including covariates that were statistically significant in 
multivariate regression was generated and its performance evaluated through the metrics 
of discrimination and calibration.  
Family history of premature CHD was statistically significant among men, but not 
among women (p=0.068). Waist hip ratio was marginally significant among women 
(p=0.052), but the addition of waist hip ratio rendered BMI no longer significant (0.946) 
among men. Table 6 describes each covariate’s regression coefficient and the 
corresponding standard error and p value. 
When stratified by sex and race, BMI was significant among white women but 
statistically not significant among white men (p=0.34), black women (p=0.445) and black 
men (p=0.535). On the other hand, waist hip ratio was significant among blacks and 
white men, but statistically not significant among white women (p=0.338). Family 
history of premature CHD was statistically not significant among white women 
(p=0.127), black women (p=0.195) and black men (p=0.971), but significant among 
white men. In addition, untreated systolic blood pressure was not statistically significant 
among black men (p=0.101). Table 6 describes the regression coefficients for the 





Table 6: Regression coefficients of the adjusted non-LB model stratified by sex and race 
Adjusted non-LB 
model covariates 
Female coefficients stratified by race 
 
Male coefficients stratified by race 
 
 
women white women black women men white men black men 

















































N/A N/A N/A N/A 













Family hx of 
premature CHD 




































Standard errors in brackets, N/A= not applicable 
* p<0.05, ** p<0.01, *** p<0.001, γ p≤0.1 
 
There was no difference in discrimination between the adjusted and unadjusted 
non-LB models. Women maintained a C statistic of 0.75 (95% CI, 0.73-0.77) compared 
to men’s 0.67 (95% CI, 0.66-0.69). When stratified by sex and race, there was no 
significant difference in discrimination. white women had a C statistic of 0.746 (95% CI, 
0.72-0.77) compared to black women’s 0.748 (95% CI, 0.71-0.78), while white men had 
a C statistic of 0.675 (95% CI, 0.65-0.69) compared to black men’s 0.689 (95% CI, 0.65-
0.72).  
There was minimal improvement in calibration with women still maintaining 
good calibration compared to men with Hosmer-Lemeshow goodness of fit (df 8) χ 2= 
12.4 (p=0.189) versus 21.2 (p=0.0115) respectively. When stratified by sex and race, 
calibration was good in all groups stratified by sex and race. 





  The adjusted LB model 
To improve the LB Framingham model, variables that included BMI, waist hip 
ratio, family history of premature CHD, apolipoprotein A and apolipoprotein B were 
added to the model.  A new model (adjusted LB model) including covariates that were 
statistically significant in multivariate regression was generated and its performance 
evaluated through the metrics of discrimination and calibration.  
Total cholesterol, waist hip ratio and family history of premature CHD were 
statistically significant in predicting CVD events among men, but not among women (p= 
0.765 and 0.327 and 0.106 respectively). On the other hand, apolipoprotein B was 
significant among women but not among men (p=0.969) as shown in Table 7. BMI and 
apolipoprotein A were not significant among women (p= 0.592 and 0.585 respectively) or 
men (p= 0.288 and 0.938 respectively). All other variables were significant in both sexes 
as described in Table 7. 
When stratified by sex and race, apolipoprotein B was significant among white 
women but not significant among black women (p=0.238), white men (p=0.953) and 
black men (p=0.853), waist hip ratio was significant among blacks and white men, but 
statistically not significant among white women (p=0.897). Family history of premature 
CHD was statistically not significant among white women (p=0.148), black women 
(p=0.224) and black men (p=0.955), but was significant among white men. In addition, 







Table 7: Regression coefficients of the adjusted LB model stratified by race and sex 
Adjusted LB 
model covariates 
Female coefficients stratified by race 
 
Male coefficients stratified by race 
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cholesterol 

























N/A N/A N/A N/A 











Family hx of 
premature CHD 




































N 6352 4757 1597 4406 3612 1093 
Standard errors in brackets, N/A= not applicable 
* p<0.05, ** p<0.01, *** p<0.001, γ p<0.1 
 
There was no difference in discrimination between the adjusted and unadjusted 
LB models. Women had a C statistic of 0.76 (95% CI, 0.74-0.78) compared to men’s 
0.69 (95% CI, 0.67-0.71). When stratified by sex and race, there was no significant 
difference in discrimination. white women had a C statistic of 0.755 (95% CI, 0.73-0.78) 
compared to black women’s 0.753 (95% CI, 0.72-0.79), while white men had a C statistic 




Both sexes had similar calibration with Hosmer-Lemeshow goodness of fit (df 8) 
χ 2= 18.6 among women (p=0.0289) versus 18.1 (p=0.0343) among men. When stratified 
by sex and race, calibration was good in all groups except among white men with 
Hosmer-Lemeshow goodness of fit (df 8) χ 2= 20.3 (p=0.0164). 
c)  Applicability of the Framingham algorithms in the ARIC sample 
In this section, the published (frozen) non-LB and LB Framingham algorithms are 
imputed in the ARIC dataset and applied to stratify CVD risk in the ARIC sample. In 
addition, two more risk prediction functions (recalibrated Framingham and adjusted 
algorithms) are derived using ARIC dataset, and their performance in stratifying CVD 
risk compared to the frozen Framingham algorithms using kappa statistic and 
sensitivity/specificity analysis. The three CVD risk prediction algorithms adhere to the 
general formulae outlined in the literature review section [ 𝑝 =  1 −
S0(𝑡)
exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−∑ =1 
𝑝
𝑖 ?̇?𝑖?̅?𝑖)] which is widely used in Framingham and other studies to 
generate CVD risk prediction algorithms.  
The frozen Framingham algorithms simply adopt all features of the published 
Framingham risk prediction functions, while the recalibrated algorithms alter the 
published Framingham functions by substituting their baseline survival and mean of risk 
factors with ARIC generated baseline survival and mean of risk factors. The adjusted 
algorithms alter the published Framingham risk function by substituting their baseline 
survival, covariates and regression coefficients with those generated in ARIC.  
  CVD risk stratification using the frozen Framingham algorithms 
The frozen non-LB Framingham algorithm calculates the 10-year CVD risk for 
women as 𝑝 = 1 − 0.94833exp (∑ =1 
𝑝




𝑝 = 1 − 0.88431exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−23.9388). On the other hand, the frozen LB Framingham 
algorithm calculates the risk for women as 𝑝 =  1 − 0.95012 exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−26.1931), and 
the risk for men as 𝑝 =  1 − 0.88936 exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−23.9802). In addition to using the 
Framingham’s baseline survival and mean of risk factors, the frozen Framingham 
algorithms also use the Framingham generated regression coefficients (?̇?𝑖) in the 
equations above. 
When the frozen Framingham algorithms were applied to stratify CVD risk in the 
entire ARIC sample, the outcome was comparable in all risk categories.  For instance, the 
non-LB Framingham algorithm classified 18% of the sample as high or very high risk 
(see Figure 11 below) compared to 17% by the frozen LB Framingham algorithm (Figure 
12 below). When the four risk categories stratified by the two frozen Framingham 
algorithms were compared by kappa test, there was an overall agreement of 92.76% and a 























































Entire ARIC cohort, 4 risk strata








Entire ARIC cohort, 4 risk strata









Frozen LB Framingham algorithm 
 low moderate high very 
high 
Total 
low 5,696 809 9 0 6,514 
moderate 392 2,241 443 31 3,107 
high 3 350 642 198 1,193 
very high 0 16 208 563 787 
total  6,091 3,416 1,302 792 11,601 
Ratings weighted by: 
1.0000 0.6667 0.3333 0.0000 
0.6667 1.0000 0.6667 0.3333 
0.3333 0.6667 1.0000 0.6667 
0.0000 0.3333 0.6667 1.0000 
Agreement Expected 
Agreement 
Kappa Std. Err. Z Prob>Z 
92.76% 69.56% 0.7624 0.0069 111.28 0.0000 
 
 When the frozen non-LB Framingham algorithm was used to classify CVD risk in 
the ARIC sample stratified by sex and race, a greater proportion of black women and 
black men were classified as high or very high risk compared to their white counterparts. 
The proportion of black women in the high risk category was 4.3% more than the 
proportion of white women (7.8% versus 3.5% respectively), while the proportion of 
black women in the very high risk category was 4.4% more than the proportion of white 
women (5.9% versus 1.5% respectively) as depicted in Figure 13 below.  
Among men, blacks dominated the high and very high risk categories. The 
proportion of black men in the high risk category was 6.2% higher compared to white 
men (24.2% versus 18.0% respectively). In the very high risk category, the proportion of 
black men was 10% higher than the proportion of white men (19.9% versus 9.9% 







Figure 13: Frozen non-LB Framingham algorithm risk categories stratified by sex & race 
 
 
When the frozen LB Framingham algorithm was applied to classify CVD risk in 
the ARIC sample stratified by sex and race, higher proportions of blacks dominated the 
high and very high risk categories compared to whites. The proportion of black women in 
the high risk category was 3.5% higher than the proportion of white women (6.8% versus 
3.3% respectively), while the proportion of black women in the very high risk category 
was 2.8% higher than the proportion of white women (4.4% versus 1.6% respectively) as 
depicted in Figure 14 below. Among men, the differences in the high and very high risk 
categories were minimal, with 20.1% of black men and 17.1% of white men being 
classified as high risk (3% difference), and 15% of black men versus 11.4% of white men 








































Figure 14: Frozen LB Framingham algorithm risk categories stratified by sex & race 
 
 
  CVD risk stratification using the recalibrated Framingham algorithms 
Recalibration of the Framingham algorithms was done by replacing their baseline 
survival and mean of risk factors with values generated in the ARIC sample, but the 
Framingham generated regression coefficients (?̇?𝑖) were retained. In the ARIC sample, 
the baseline survival adjusted for the non-LB covariates was 0. 9111038 for women and 
0.8335824 for men. The baseline survival adjusted for the LB covariates was 
0.9033732 and 0.8461685 for women and men respectively in the ARIC sample. 
Therefore, the recalibrated non-LB algorithm calculates the 10-year CVD risk for 
women as 𝑝 = 1 − 0. 9111038exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−27.127605) ; while the risk for men is 
calculated as 𝑝 = 1 − 0.8335824exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−24.78308). On the other hand, the 
recalibrated LB algorithm calculates the risk for women as 𝑝 =  1 −
0.9033732 exp (𝐴 ∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−27.18902), and the risk for men as  𝑝 =  1 −
0.8461685 exp(∑ =1 
𝑝











































Data source: ARIC 1987-1999








When the recalibrated algorithms were applied to stratify CVD risk in the entire 
ARIC sample, the outcome was comparable in all risk categories.  For instance, the 
recalibrated non-LB algorithm classified 7.44% of the sample as high or very high risk 
compared to 8.09% by the recalibrated LB algorithm. When the four risk categories 
stratified by the two recalibrated algorithms were compared by kappa test, there was an 
overall agreement of 94.26% and a kappa statistic of 0.72. 
When the recalibrated algorithms were applied to classify CVD risk in the ARIC 
sample stratified by sex and race, there was no difference between the non-LB and LB 
algorithm, or between blacks and whites. However, higher proportions of men were 
classified in the high and very high risk strata compared to women in both racial groups 
by both algorithms as described in Figures 15 and 16. 
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Figure 16: Recalibrated LB algorithm risk categories stratified by sex & race 
 
 
  CVD risk stratification using the adjusted algorithms 
The adjusted algorithms were generated by replacing the baseline survival, mean 
of risk and regression coefficients of the general CVD formulae with values generated in 
the ARIC sample. In the ARIC sample, the baseline survival adjusted for the additional 
non-LB covariates (described in the mathematical performance section) was 0. 908755 
for women and 0.8518082 for men. The baseline survival for the adjusted LB covariates 
was 0.9032351 and 0.8568301 for women and men respectively in the ARIC sample. 
Therefore, the adjusted non-LB algorithm calculates the 10-year CVD risk for 
women as 𝑝 = 1 − 0.908755 exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−26.73064) ; while the risk for men is calculated 
as 𝑝 = 1 − 0.8518082exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−21.26414). On the other hand, the adjusted LB 
algorithm calculates the risk for women as 𝑝 =  1 − 0.9032351 exp (∑ =1 
𝑝
𝑖 ?̇?𝑖𝑋𝑖−27.747355), 
and the risk for men as 𝑝 =  1 − 0.8568301  exp (∑ =1 
𝑝



























low moderate high very high low moderate high very high
female, White female, Black












When the adjusted algorithms were applied to stratify CVD risk in the entire 
ARIC sample, there was no difference between categories.  For instance, the adjusted 
non-LB algorithm classified 6.88% of the sample as high or very high risk compared to 
5.90% by the adjusted LB algorithm. When the four risk categories stratified by the two 
algorithms were compared by kappa test, there was an overall agreement of 96.12% and a 
kappa statistic of 0.7996. 
When the adjusted algorithms were applied to classify CVD risk in the ARIC 
sample stratified by sex and race, there was no difference between the non-LB and LB 
algorithm, or between blacks and whites. However, higher proportions of men were 
classified in the high and very high risk strata compared to women in both racial groups 
by both algorithms as described in Figures 17 and 18. 
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Figure 18: Adjusted LB algorithm risk categories stratified by sex & race 
 
 
d) Sensitivity/specificity analysis  
 Sensitivity/specificity analysis was done to determine the clinical usefulness of 
the non-LB and LB versions of the three algorithms described above. Sensitivity of 
each algorithm was determined by the proportion of the sample with incident CVD 
who are correctly identified as high risk by the algorithm. Specificity was dictated by 
the proportion of the sample without incident CVD who were classified as low risk by 
the algorithm. The roctab command in Stata© was used to calculate and plot the 
nonparametric AUROC based on sensitivity/specificity analysis for each algorithm.  
  Sensitivity/specificity analysis of the frozen Framingham algorithms 
 Although the Framingham algorithms are ideally intended to predict CVD risk 
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discussed in the methods section.  Therefore, the analysis described in this section 
focuses on their sensitivity/specificity analysis within 12 years’ time frame.  
   The frozen non-LB Framingham algorithm 
In the entire ARIC sample, the frozen non-LB Framingham algorithm had an 
overall AUROC of 0.7063.  At the moderate risk category (10-20%), the algorithm had a 
sensitivity of 76% and specificity of 57.03%. When the high risk (20-30%) cut point was 
used as the threshold for predicted incident CVD, the algorithm had a sensitivity of 
41.10% versus specificity of 85.49%. Table 9 below describes a detailed report of the 
algorithm’s sensitivity and specificity at the four different risk cut points described in the 
methods section, while Figure 19 plots the resultant AUROC. 
Table 9: Sensitivity/specificity analysis of the frozen non-LB Framingham algorithm 
Any CVD event within first 
12yrs of follow-up 
Frozen non-LB based Framingham risk categories in ARIC 
        low    moderate        high   very high       Total 
CVD free      5,735       2,862         965         494      10,056  
Incident CVD        356         554         337         298       1,545  
Total      6,091       3,416       1,302         792      11,601  
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00% 0.00% 13.32% 1.0000  
>=moderate risk (10-20%) 76.96% 57.03% 59.68% 1.7910 0.4040 
>=high risk (20-30%) 41.10% 85.49% 79.58% 2.8328 0.6890 
>=very high risk (>30% ) 19.29% 95.09% 84.99% 3.9263 0.8488 
> very high risk  0.00% 100.00% 86.68% 1.0000  
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
11,601     0.7063       0.0068        0.69294     0.71969 
Sensitivity= fraction of true positive cases 
Specificity= fraction of true negative cases 








Figure 19: Frozen non-LB Framingham AUROC for entire ARIC sample 
 
 
When the ARIC sample was stratified by sex and race, the algorithm’s AUROCs 
for women and blacks were higher compared to men and whites respectively. Figures 20-
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 Figure 20: Frozen non-LB Framingham AUROC    Figure 21: Frozen non-LB Framingham AUROC  
 white women              black women 
 
                                                                              
           Figure 22: Frozen non-LB Framingham AUROC     Figure 23: Frozen non-LB Framingham AUROC   
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   The frozen LB Framingham algorithm 
In the entire ARIC sample, the frozen LB Framingham algorithm had an overall 
AUROC of 0.71. At the moderate risk (10-20%) threshold, the algorithm had a sensitivity 
of 74.63% and specificity of 60.88%. When the high risk (20-30%) cut point is used as 
the threshold for predicted incident CVD, the algorithm had a sensitivity of 40.32% 
versus specificity of 86.51%. Table 10 below describes a detailed report of the 
algorithm’s sensitivity and specificity at the four different risk cut points described in the 
methods section, while Figure 24 plots the resultant AUROC. Both frozen Framingham 
algorithms (non-LB and LB) had similar AUROCs with no statistical difference in their 
sensitivity and specificity (p=0.3661) as depicted in Figure 25. 
Table 10: Sensitivity/specificity analysis of the frozen LB Framingham algorithm 
Any CVD event within first 
12yrs of follow-up 
Frozen LB based Framingham risk categories in ARIC 
        low    moderate        high   very high       Total 
CVD free 6,122 2,577 880 477 10,056 
Incident CVD 392 530 313 310 1,545 
Total 6,514 3,107 1,193 787 11,601 
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00% 0.00% 13.32% 1.0000  
>=moderate risk (10-20%) 74.63% 60.88% 62.71% 1.9076 0.4168 
>=high risk (20-30%) 40.32% 86.51% 80.36% 2.9882 0.6899 
>=very high risk (>30% ) 20.06% 95.26% 85.24% 4.2300 0.8392 
> very high risk  0.00% 100.00% 86.68%  1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
11,601     0.7100     0.0068        0.69661     0.72345 
Sensitivity= fraction of true positive cases 
Specificity= fraction of true negative cases 








Figure 24: Frozen LB Framingham AUROC for entire ARIC sample 
 
 
Figure 25: Comparing frozen Framingham algorithms’ AUROCs in entire ARIC sample 
 
 
When the ARIC sample was stratified by sex and race, the frozen LB 
Framingham algorithm’s AUROCs for blacks were higher compared to whites. Figures 
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    Figure 26: Frozen LB Framingham AUROC         Figure 27: Frozen LB Framingham AUROC 





        Figure 28: Frozen LB Framingham AUROC        Figure 29: Frozen LB Framingham AUROC  
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  Sensitivity/specificity analysis of the recalibrated algorithms 
   The recalibrated non-LB algorithm  
 In the entire ARIC sample, the recalibrated non-LB algorithm had an overall ROC 
of 0.6711.  At the moderate risk category (10-20%), the algorithm had a sensitivity of 
58.58% and specificity of 73.45%. When the high risk (20-30%) cut point was used as 
the threshold for predicted incident CVD, the algorithm had a sensitivity of 20.13% 
versus specificity of 94.51%. Table 11 below describes a detailed report of the 
algorithm’s sensitivity and specificity at the four different risk cut points, while Figure 30 
plots the resultant AUROC. 
Applied to the ARIC sample stratified by sex and race, the recalibrated algorithm 
had the highest AUROC for black women (0.6691) followed by black men (0.6577). 
white men had a higher AUROC (0.6383) compared to white women (0.5890).  
Table 11: Sensitivity/specificity analysis of the recalibrated non-LB algorithm 
Any CVD event within first 
12yrs of follow-up 
Recalibrated non-LB algorithm risk categories in ARIC 
        low    moderate        high   very high       Total 
CVD free 7,386      2,118         431         121 10,056 
Incident CVD 640                   594 226 85 1,545 
Total 8,026               2,712         657 206 11,601      
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00%          0.00%        13.32%        1.0000       
>=moderate risk (10-20%) 58.58%         73.45%        71.47%        2.2061        0.5640 
>=high risk (20-30%) 20.13%         94.51%        84.60%        3.6671        0.8451 
>=very high risk (>30% ) 5.50%         98.80%        86.37%        4.5723        0.9565 
> very high risk  0.00%               100.00% 86.68%                      1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
11,601     0.6711       0.0069        0.65745     0.68469 






Specificity= fraction of true negative cases 
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)  
 
 
Figure 30: Recalibrated non-LB Framingham AUROC for entire ARIC sample 
 
 
   The recalibrated LB algorithm 
 In the entire ARIC sample, the recalibrated LB algorithm had an overall AUROC 
of 0.6851.  At the moderate risk category (10-20%), the algorithm had a sensitivity of 
60.84% and specificity of 73.73%. When the high risk (20-30%) cut point was used as the 
threshold for predicted incident CVD, the algorithm had a sensitivity of 22.46% versus 
specificity of 94.12%. Table 12 below describes a detailed report of the algorithm’s 
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Applied to the ARIC sample stratified by sex and race, the recalibrated LB 
algorithm had similar AUROC for black men (0.6648) and white men AUROC (0.6644). 
black women had a higher AUROC (0.6622) compared to white women (0.6230).  
 
Table 12: Sensitivity/specificity analysis of the recalibrated LB algorithm 
Any CVD event within first 
12yrs of follow-up 
Recalibrated LB risk categories in ARIC 
        low    moderate        high   very high       Total 
CVD free 7,414              2,051         444 147 10,056 
Incident CVD 605                       593 226 121 1,545 
Total 8,019               2,644         670 268 11,601      
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00%          0.00%        13.32%        1.0000       
>=moderate risk (10-20%) 60.84%         73.73%        72.01%        2.3158        0.5311 
>=high risk (20-30%) 22.46%         94.12%        84.58%        3.8215        0.8238 
>=very high risk (>30% ) 7.83%                98.54%        86.46% 5.3575        0.9354 
> very high risk  0.00%        100.00%        86.68%                     1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
11,601     0.6851       0.0069        0.67158     0.69868 
Sensitivity= fraction of true positive cases 
Specificity= fraction of true negative cases 
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)  
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  Sensitivity/specificity analysis of the adjusted algorithms 
   The adjusted non-LB algorithm 
 In the entire ARIC sample, the adjusted non-LB algorithm had an overall 
AUROC of 0.6768.  At the moderate risk category (10-20%), the algorithm had a 
sensitivity of 56.77% and specificity 76.20%. When the high risk (20-30%) cut point was 
used as the threshold for predicted incident CVD, the algorithm had a sensitivity of 
21.02% versus specificity of 95.23%. Table 13 below describes a detailed report of the 
algorithm’s sensitivity and specificity at the four different risk cut points, while Figure 32 
plots the resultant AUROC. 
When applied to the ARIC sample stratified by sex and race, the adjusted non-LB 
algorithm had the highest AUROC in black women (0.6793), while white women had the 
lowest AUROC (0.6066). White men had similar AUROC (0.6568) with black men 
(0.6580). 
Table 13: Sensitivity/specificity analysis of the adjusted non-LB algorithm 
Any CVD event within first 
12yrs of follow-up 
Adjusted non-LB categories in ARIC 
        low    moderate        high   very high       Total 
CVD free 6,470 1,616         271 134 8,491 
Incident CVD 549                         454 151 116 1,270 
Total 7,019               2,070         422 250 9,761 
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00%          0.00%        13.01%        1.0000  
>=moderate risk (10-20%) 56.77%         76.20%        73.67%        2.3852        0.5673 
>=high risk (20-30%) 21.02%         95.23%        85.58%        4.4077        0.8293 
>=very high risk (>30% ) 9.13%               98.42% 86.80%        5.7877        0.9232 
> very high risk  0.00%        100.00%        86.99%                      1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
9,761     0.6768       0.0077        0.66183     0.69187 
Sensitivity= fraction of true positive cases; Specificity= fraction of true negative cases 







Figure 32: Adjusted non-LB algorithm AUROC for entire ARIC sample
 
 
   The adjusted LB algorithm 
 In the entire ARIC sample, the adjusted LB algorithm had an overall AUROC of 
0.6908.  At the moderate risk category (10-20%), the algorithm had a sensitivity of 
58.98% and specificity of 76.73%. When the high risk (20-30%) cut point was used as the 
threshold for predicted incident CVD, the algorithm had a sensitivity of 22.05% versus 
specificity of 95.24%. Table 14 below describes a detailed report of the algorithm’s 
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Applied to the ARIC sample stratified by sex and race, the adjusted LB algorithm 
had the highest AUROC for black women (0.7033) followed by white men (0.6783). 
black men had a higher AUROC (0.6411) compared to white women (0.6317).  
Table 14: Sensitivity/specificity analysis of the adjusted LB algorithm 
Any CVD event within first 
12yrs of follow-up 
Adjusted LB categories in ARIC 
        low    moderate        high   very high       Total 
CVD free     6,515              1,572         288 116 8,491 
Incident CVD 521                        469 163 117 1,270 
Total 7,036      2,041         451         233 9,761 
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00%          0.00%        13.01%        1.0000       
>=moderate risk (10-20%) 58.98%         76.73%        74.42%        2.5343        0.5347 
>=high risk (20-30%) 22.05%  95.24%       85.72%        4.6337        0.8185 
>=very high risk (>30% ) 9.21%         98.63%        87.00%        6.7435        0.9204 
> very high risk  0.00%        100.00%        86.99%                      1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
9,761     0.6908       0.0076        0.67592     0.70574 
Sensitivity= fraction of true positive cases; Specificity= fraction of true negative cases 
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)  
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  Comparing sensitivity/specificity of all algorithms 
When all non-LB algorithms (frozen, recalibrated and adjusted) were compared in 
the entire ARIC sample, the frozen non-LB Framingham had the highest AUROC 
(0.7086), while the recalibrated model had the lowest (0.6697) as described in Figure 34 
below. Among the LB algorithms, the frozen non-LB algorithm had the highest AUROC 
(0.7141) while the recalibrated algorithm had the lowest (0.6868) as depicted in Figure 
35 below. 
When the frozen LB Framingham algorithm was compared to all non-LB 
algorithms in the entire ARIC sample, the frozen LB Framingham had the highest 
AUROC (0.7141) followed by the frozen non-LB Framingham (0.7086). The recalibrated 
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e) Simulated cost-effectiveness analysis of the non-LB Framingham algorithm  
 Introduction 
To determine the cost-effectiveness of the non-LB Framingham algorithm, the 
expenses and outcomes associated with the three simulated CVD prevention programs 
described in the methods were calculated. The expenses were costed at three levels which 
are consistent with the steps inherent in CVD prevention programs. Level I expenses are 
the screening costs and are determined by the unit cost of screening an individual in each 
program. Level II expenses are the costs of preventive interventions prescribed in each 
program and are driven by the number of true and false positive cases associated with 
each program. Level III expenses includes the downstream costs of treating false negative 
cases associated with each preventive program. The outcomes describing the 
effectiveness of each program were quantified by identifying the true positive cases 
associated with each preventive program. 
The costs and outcomes associated with each program were used to compute their 
respective average cost-effectiveness ratios. Finally, incremental cost-effectiveness 
analysis was done where existing programs (status quo) were considered to be the 
individual risk factors and LB absolute risk approaches to CVD prevention, while the 
new program was considered to be the non-LB absolute risk approach.   
 Level I:  Expenses in screening for CVD 
Level I expenses are the over-time, non-recurring marginal costs incurred during a 
patient’s first routine office visit when the provider screens a patient to assess CVD risk. 
These expenses include the extra Registered Nurses (RN) hours spent taking a patient’s 






visit itself is not costed because the cost is incurred regardless of whether CVD screening 
takes place or not. 
 It has been estimated that an individual’s absolute risk score can be calculated 
within ten minutes using non-LB algorithms because the only data required include: sex, 
age, smoking status, diabetes status, antihypertensive medication use, systolic blood 
pressure and BMI (D'Agostino RB et al., 2008; Gaziano et al., 2008). For purposes of this 
study, the RN time required to appraise CVD risk based on individual risk factors 
(diabetes and/or hypertension) was estimated to be 5 minutes because only the 
demographic and relevant history/physiologic data are collected without calculating any 
risk scores. The RN screening time using the LB Framingham algorithm was assumed to 
be similar to the non-LB algorithm since the extra time for assessing lipids was costed 
under the laboratory expenses.   
The basic equipment needed for either preventive approach (i.e. weighing scale, 
tape measure, glucometer and sphygmomanometer) are readily available in most primary 
care offices; hence no additional capital inputs are required for screening. The diagnostic 
cost of blood glucose testing for diabetes is required for the three CVD prevention 
programs.  The LB absolute risk approach has additional diagnostic costs for HDL and 
total cholesterol tests. The absolute CVD risk score can be calculated for both approaches 
by an interactive online calculator or an offline calculator embedded in a downloadable 
excel spread sheet. Alternatively, the absolute CVD risk scores can be calculated 
manually by a paper based tool that aggregates points associated with each covariate 
included in the Framingham algorithms.  Both the online and offline calculators, and the 






assumed use of the offline calculators, because of their efficiency and applicability to 
settings without internet connection. 
All costs were based on Mississippi payment rates because most of the black 
participants in ARIC were recruited from Jackson, Mississippi (ARIC Investigators, 
1989). The RN hourly wage is based on Bureau of Labor Statistics median RN hourly 
wage for the state of Mississippi which is $27.19/hr. (Bureau of Labor Statistics, 2014). 
Since the Centers for Medicare and Medicaid (CMS) have well established 
reimbursement rates for diagnostic tests, screening for diabetes and lipids were costed 
based on the 2016 clinical diagnostic laboratory fee schedule in Mississippi. 
Reimbursement for diabetes was calculated using Current Procedure Terminology (CPT 
code 82962 ($3.19) while HDL and total cholesterol tests were costed under CPT codes 
83718 ($11.16) and 82465 ($5.92) respectively (Centers for Medicare & Medicaid 
Services, 2015a). Medicare rates were assumed close to true marginal costs because 
many tests are conducted at these rates which are lower than with private insurance. 
The screening costs are calculated for each CVD prevention strategy in equations 
1a-c and summarized in Table 15. Both approaches will incur costs for screening the 
2,690 eligible black sample in the ARIC dataset. 
Equation 1a: The individual CVD risk factors (DM/HTN) approach:       
Screenr =  2690  individuals ∗ [(5min ∗ $0.45) + $3.19] = $14,634 
 Equation 1b: The non-LB absolute CVD risk approach: 
Screena =  2690 individuals ∗ [(10min ∗ $0.45) + $3.19] = $20,686 
 Equation 1c: The LB absolute CVD risk approach: 






Table 15: Marginal screening costs: individual risk factors vs absolute non-LB vs LB 
absolute risk approach 
Costed screening items  Individual risk factors 
(DM/HTN) 
Absolute CVD risk  
(non-LB Framingham ) 
Absolute CVD risk 
(LB Framingham ) 
RN screening min/person 5 mins 10 mins 10 mins 
RN hourly wage ($27.19/hr.) $0.45/min $0.45/min $0.45/min 
Fasting glucose test cost $3.19 $3.19 $3.19 
HDL test $0 $0 $11.16 
Total cholesterol test $0 $0 $5.92 
Total Screening costs/person $5.44 $7.69 $24.77 
Total Screening costs  $14,634 $20,686.1 $66,631.3 
  Screening time is estimated as suggested by Gaziano et al. (2008) 
  RN wages are the 2014 average RN wages for Mississippi reported by Bureau of Labor Statistics. 
  Fasting glucose, HDL and total cholesterol test costs are based on reimbursement for CPT codes 82962, 83718 and   
  82465 respectively in Mississippi 
 
Level II:  Expenses of initial and follow-up visits for positive cases 
If a patient is determined to be at risk for CVD, guidelines recommend a battery 
of follow-up steps. Initial and follow-up office visits are costed using the Medicare 
physician fee schedule. The drugs prescribed by each CVD prevention approach (see 
Figure 3 and Table 2) are identified by their National Drug Code (NDC), and costed 
using the National Average Drug Acquisition Cost (NADAC) compiled by Medicaid in 
the last week of December 2015 (Centers for Medicare & Medicaid Services, 2015c; 
Medicaid.gov, 2016).  
Level II expenses are influenced by the number of participants classified above a 
certain risk threshold and the cost of interventions prescribed by each CVD preventive 
strategy (see Table 2 for absolute CVD risk programs and Figure 3 for individual risk 
factors program). A CVD preventive strategy with many false positives unnecessarily 






The moderate risk category (absolute CVD risk score ≥10) was selected as the 
optimal risk threshold for the absolute CVD risk programs and the high risk category 
(presence of diabetes and/or hypertension) for the individual CVD risk factor program. 
These thresholds were based on sensitivity/specificity analyses outlined in Table 16 (for 
the individual CVD risk factors program) and Table 17 and 18 (for the absolute CVD risk 
programs). 
When the high risk category was applied as the treatment threshold in the 
approach based on treating individual CVD risk factors, there were 1045 true negatives 
and 88 false negatives, along with 313 true positives and 1244 false positives as detailed 
in Table 16. The false and true negatives (1133 cases) were not be prescribed the 
preventive treatments outlined in Figure 3, and did not contribute to level II expenses. On 
the other hand, the false and true positives (1557) received the preventive interventions 
and contributed to level II expenses.  
Table 16: Sensitivity/specificity analysis of the individual risk factors strategy 
Any CVD event within first 12yrs 
of follow-up 
Individual risk factors (DM/HTN) risk categories in 
ARIC 
 low High Total 
CVD free 1,045 1,244 2,289 
Incident CVD 88 313 401 
Total 1,133 1,557 2,690 
Detailed report of sensitivity and specificity                                   
Cut point Sensitivity    Specificity    Correctly Classified           LR+      LR- 
>=low risk  100.00%          0.00%        14.91%        1.0000       
>=high risk  78.05% 45.65%        50.48%        1.4362        0.4807 
> high risk 0.00%         100.00%        85.09%                1.0000 
                                                 ROC                    -Asymptotic Normal-- 
                                   Obs       Area      Std. Err.      [95% Conf. Interval] 
                                   ------------------------------------------------------------ 
                                       2,690    0.6185       0.0116        0.59584     0.64124 
Sensitivity= fraction of true positive cases 
Specificity= fraction of true negative cases 






Using the non-LB moderate risk category, the absolute CVD risk prevention 
strategy has 1094 true negatives and 72 false negatives, along with 329 true positives and 
1195 false positives as detailed in Table 17. The true and false positives (1524) contribute 
to level II interventions because they receive the preventive interventions described in 
Table 2 depending on absolute CVD risk score. The false positive category drives up 
level II expenses while not preventing CVD events.  
Table 17: Sensitivity/specificity analysis of the non-LB guided absolute CVD risk strategy 
Any CVD event within first 
12yrs of follow-up 
Frozen non-LB based Framingham risk categories in ARIC 
        low    moderate        high   very high       Total 
CVD free 1,094 704 296 195 2,289 
Incident CVD 72 120 93 116 401 
Total 1,166 824 389 311 2,690 
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+      LR- 
>=low risk (<10%) 100.00% 0.00% 14.91% 1.0000  
>=moderate risk (10-20%) 82.04% 47.79% 52.90% 1.5716 0.3757 
>=high risk (20-30%) 52.12% 78.55% 74.61% 2.4298 0.6096 
>=very high risk (>30% ) 28.93% 91.48% 82.16% 3.3957 0.7769 
> very high risk  0.00% 100.00% 85.09%  1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
2,690     0.7061       0.0136        0.67938     0.73277 
Sensitivity= fraction of true positive cases 
Specificity= fraction of true negative cases 
Correctly classified= percentage correctly classified in their true disease state (CVD or no CVD)  
 
When the moderate risk category of the LB Framingham algorithm was applied as 
the treatment threshold, the absolute CVD risk prevention strategy guided by the 
algorithm had 1,292 true negatives and 92 false negatives, along with 309 true positives 
and 997 false positives as detailed in Table 18. The false and true negatives (1,384 cases) 






for this group. The false and true positives (1,306 cases) received the preventive 
interventions described in Table 2 and hence contributed to level II expenses. 
Table 18: Sensitivity/specificity analysis of the LB guided absolute CVD risk strategy 
Any CVD event  Frozen lab based Framingham risk categories in ARIC 
        low    moderate        high   very high  Total 
CVD free 1,292                       616 242   139 2,289 
Incident CVD 92                         128    86 95 401 
Total  1,384                         744 328 234 2,690 
Detailed report of sensitivity and specificity                                 
Cut point Sensitivity    Specificity    Correctly 
Classified       
    LR+     LR- 
>=low risk (<10%) 100.00% 0.00% 14.91% 1.0000  
>=moderate risk (10-20%) 77.06%         56.44%        59.52%        1.7692        0.4065 
>=high risk (20-30%) 45.14%         83.36%        77.66%        2.7118        0.6582 
>=very high risk (>30% ) 23.69%               93.93%        83.46% 3.9013        0.8124 
> very high risk  0.00% 100.00% 85.09%  1.0000 
           ROC                    -Asymptotic Normal-- 
Obs       Area     Std. Err.      [95% Conf. Interval] 
------------------------------------------------------------ 
  2,690     0.7077       0.0136        0.68097     0.73441 
 
Whereas the true and false negatives in all programs do not contribute to level II 
expenses because follow-up is not recommended, the false negative cases end up missing 
the preventive interventions required to prevent CVD events. Treatment of CVD events 
observed among the false negative cases contribute to level III expenses. 
Level II expenses are subcategorized into costs associated with initial and follow-
up office visits, and costs associated with the drugs prescribed by each preventive 
strategy. These costs are discussed and calculated below. Although in clinical settings the 
CPT coding varies depending on specific problems and complexity of the office visit, this 
analysis assumed uniform complexity of all visits using CPT code 99203 that requires 
medical decision making of moderate complexity. The visit typically lasts for 45 minutes 






(Centers for Medicare & Medicaid Services, 2015b). The 2015 physician office 
reimbursement for CPT code 99203 was $100.28 in Mississippi (Centers for Medicare & 
Medicaid Services, 2015c). 
   Costs associated with initial office visits 
The initial office visits in this analysis are expected to occur immediately after 
screening for all individuals who meet the treatment threshold. The initial office visits are 
costed on an annual basis for each CVD prevention strategy in equation 2a-c below. 
The individual CVD risk factors approach initial office visit costs: 
For the individual risk factors approach, the initial visits included a total of 1557 
individuals (true and false positives) who met the treatment threshold for the strategy 
discussed above. The total costs of these initial office visits (IVrc) are estimated in 
equation 2a: 
 𝑓(IVrc) = 1557 individuals ∗ 1 visit  ∗  $100.28 = $156,135.96 
The non-LB absolute CVD risk strategy initial office visit costs: 
 For the non-LB absolute CVD risk strategy, initial visits included a total of 1524 
individuals (true and false positives) who met the treatment threshold. The total costs of 
these initial office visits (IVac) are estimated in equation 2b: 
𝑓(IVac) = 1524 individuals ∗ 1 visit ∗  $100.28 = $152,826.72  
The LB absolute CVD risk strategy initial office visit costs: 
For the LB absolute CVD risk strategy, initial visits included a total of 1,306 individuals 
(true and false positives) who met the treatment threshold. The total costs of these initial 
office visits (IVlc) are estimated in equation 2c: 






   Costs associated with follow-up office visits 
The follow-up office visits in this analysis were expected to occur after the initial 
office visit for all positive cases in each program. The follow-up office visits were 
scheduled at different intervals based on each individual’s absolute CVD risk score (for 
the absolute CVD risk based programs) as summarized in Table 2, or as per the IDF and 
ISH-ASH guidelines (for the individual risk factors program) outlined in Figure 3. The 
follow-up office visits are detailed and costed on an annual basis for each CVD 
prevention strategy in equation 3-5. 
The individual CVD risk factors approach follow-up costs: 
For the individual CVD risk factors strategy, follow-up office visits were only 
relevant to individuals with diabetes and/or hypertension (high CVD risk category). Since 
the IDF and ISH-ASH guidelines do not explicitly recommend a specific follow-up 
regimen, this analysis used the follow-up schedule recommended by the American 
Diabetes Association (ADA). The association recommends twice a year office visits for 
diabetic patients with stable glycemic control (American Diabetes Association, 2014). 
Follow-up for hypertension is assumed to follow the diabetes schedule. As explained 
earlier, this analysis assumed similar complexity of all office visits. Therefore, all the 
follow-up office visits were costed under CPT code 99203.  
The high risk category (presence of diabetes and/or hypertension) identified 1557 
true and false positive cases eligible for follow-up office visits scheduled every 6 months. 
The annual costs for the office visits are estimated in equation 3 and shown in Table 19 
as discounted costs.                                                                                                            






The non-LB absolute CVD risk strategy follow-up costs 
Follow-up office visits includes 824 individuals in the moderate risk category, 
389 in the high risk category and 311 in the very high risk category. The follow-up costs 
(FVac) associated with each risk category are estimated in equations (4a-c) and 
summarized in Table 19 as discounted costs. 
For the moderate risk category (10-20%), 824 follow-up office visits for treatment 
and CVD risk reduction discussion with a primary care provider are scheduled annually.  
The annual cost for these office visits is estimated in equation 4a: 
    FVac−mod =  824 individuals ∗ 1 visit/yr ∗ $100.28 =  $82630.72 
For the high risk category (20-30%), 389 follow-up office visits for treatment and 
CVD risk reduction discussion with a primary care provider are scheduled every 6 
months.  The annual costs for these office visits are estimated in equation 4b:  
  FVac−high =  389 individuals ∗ 2 visits/yr ∗ $100.28 =  $78017.84 
 For the very high risk category (>30), 311 follow-up office visits for treatment 
and CVD risk reduction discussion with a primary care provider are scheduled every 6 
months.  The annual costs for these office visits are estimated in equation 4c: 
  FVac−vhigh =  311 individuals ∗ 2 visits/yr ∗ $100.28 =  $62374.16 
Total annual cost of the follow-up office visits in all risk categories are calculated 
by summation of equations 4a-c and shown in Table 19 as discounted costs. 








The LB absolute CVD risk strategy follow-up costs 
Follow-up office visits includes 744 individuals in the moderate risk category, 
328 individuals in the high risk category and 234 individuals in the very high risk 
category. The follow-up costs (FVlc) associated with each risk category are estimated in 
equations 5a-c and summarized in Table 19 as discounted costs. 
For the moderate risk category (10-20%), 744 Follow-up office visits for 
treatment and CVD risk reduction discussion with a primary care provider are scheduled 
annually.  The annual costs for these office visits are estimated in equation 5a: 
  FVlc−mod =  744 individuals ∗ 1visit/yr ∗ $100.28 =  $74608.32 
For the high risk category (20-30%), 328 Follow-up office visits for treatment and 
CVD risk reduction discussion with a primary care provider are scheduled every 6 
months. The annual costs for these office visits are estimated in equation 5b: 
FVlc−high =  328 individuals ∗ 2 visits/yr ∗ $100.28 =  $65783.68  
 For the very high risk category (>30), 234 Follow-up office visits for treatment 
and CVD risk reduction discussion with a primary care provider are scheduled every 6 
months. The annual costs for these office visits are estimated in equation 5c: 
 FVlc−vhigh =  234 individuals ∗ 2 visits/yr ∗ $100.28 =  $46931.04   
Total annual cost of the follow-up office visits in all risk categories are calculated 
by summation of equations 5a-c:                                                                        








The annual costs associated with each year’s follow-up office visits are divided by 
the 3% discounting rate discussed under the analysis framework. Therefore, in Table 19 
the discounted annual costs for year 1 visits are divided by 1.031 and the costs for year 
12 by 1.0312 to get the respective discounted total costs for follow-up office visits. All 
costs are based on 2015 prices. 
Table 19: Discounted costs of follow-up office visits: individual risk factors vs absolute 
non-LB vs LB absolute risk approach 
 
Annual visits=True & false positives adjusted by recommended frequency of follow-up visits annually 
Discounted costs=Annual Follow-up costs discounted by (1.03) t where t= year 1 through 12 
Source: Visits based on total annual office visits expected in the ARIC cohort based on their risk profile; 
 cost based on Medicare physician fees schedule for CPT code 99203. 
Annual visits=True & false positives adjusted by recommended frequency of follow-up visits annually 
Discounted costs=Annual follow-up costs discounted by (1.03) t where t= year 1 through 12 
Source: Visits based on total annual office visits expected in the ARIC cohort based on their risk profile; 




Individual CVD risk 
factors approach 
non-LB absolute CVD 
risk approach 
LB absolute CVD risk  
approach 
 Discounted annual costs Discounted annual costs Discounted annual costs 
Year 1 $303,177 $216,527 $181,867 
Year 2 $294,346 $210,220 $176,570 
Year 3 $285,773 $204,097 $171,427 
Year 4 $277,450 $198,153 $166,434 
Year 5 $269,369 $192,381 $161,586 
Year 6 $261,523 $186,778 $156,880 
Year 7 $253,906 $181,338 $152,311 
Year 8 $246,510 $176,056 $147,875 
Year 9 $239,330 $170,928 $143,568 
Year 10 $232,360 $165,950 $139,386 
Year 11 $225,592 $161,116 $135,326 
Year 12 $219,021 $156,424 $131,385 






  Costs associated with preventive interventions 
 Besides the follow-up office visits, each CVD prevention strategy has its own set 
of preventive interventions as described in the methods section. The costs associated with 
these preventive interventions are described below. 
  The Individual CVD risk factors strategy treatment expenses 
i. Antihypertensive therapy expenses: 
The ISH-ASH guidelines recommend different treatment options depending on 
the stage of hypertension (Weber et al., 2014). In stage I hypertension (BP>140/90), 
monotherapy with either a thiazide-like diuretic or a CCB is recommended for blacks 
with or without comorbid diabetes. In stage II hypertension (BP>160/100), combined 
therapy is recommended with the second drug being an ACEI for individuals with 
comorbid diabetes (Weber et al., 2014).  
To ensure consistency in this analysis, the costing of the monotherapy treatment 
outlined in Figure 3 was done using Hydrochlorothiazide 25mg/day, while the combined 
therapy included Hydrochlorothiazide 25mg/day with Amlodipine 5mg/day in absence of 
comorbid diabetes, or Hydrochlorothiazide 25mg/day with Lisinopril 10mg/day in 
comorbid diabetes. The NADAC of Hydrochlorothiazide ((NDC 00143125601) is 
$0.01192 per 25mg tablet, Lisinopril (NDC 00143126701) $0.02011 per 10mg tablet and 
Amlodipine (NDC 76282023890) $0.01839 per 5mg tablet (Medicaid.gov, 2016).  
For the individual CVD risk factors prevention program, the high risk category 
(treatment threshold) included 1,419 individuals with blood pressure greater or equal to 
140/90 mmHg. Of these individuals, 1,230 had stage I hypertension (BP ≥ 140/90 <






In the group with stage I hypertension, 959 individuals were diabetes free, while 
271 had comorbid diabetes. The group with stage II hypertension had 134 diabetes free 
individuals and 55 with comorbid diabetes. The annual costs for treating hypertension in 
the high risk (DM/HTN) category are estimated in equations 6-7 and shown in Table 20 
as discounted costs. 
Stage I hypertension category was prescribed monotherapy with 
Hydrochlorothiazide 25mg/day even if they had comorbid diabetes as explained above. 
The annual costs for treating stage I hypertension are calculated in equation 6: 
RxhtnI±𝑑𝑚 = 1230 individuals ∗ $0.01192 ∗ 365 days =  $5351.484   
Stage II hypertension category was prescribed combined therapy with addition of 
Amlodipine or Lisinopril depending on whether or not they have comorbid diabetes as 
explained above. The annual costs for treating stage II hypertension are calculated in 
equation 7a-b. 
Equation 7a: Combined antihypertensive therapy for hypertension stage II without 
comorbid diabetes: 
RxhtnII−𝑑𝑚 = 134 individuals ∗ $0.01192 + $0.01839 ∗ 365 days =  $1482.4621   
Equation 7b: Combined antihypertensive therapy for hypertension stage II with 
comorbid diabetes: 
RxhtnII+𝑑𝑚 = 55 individuals ∗ $0.01192 + $0.02011 ∗ 365 days =  $643.00225   
The total annual costs of antihypertensive therapy in the individual CVD risk 
factor approach were calculated by summing up equations 6-7 and summarized in Table 
20 as discounted costs. 






ii. Diabetes treatment and monitoring expenses 
The IDF guidelines recommend initiating pharmacotherapy for type 2 diabetes at 
the threshold of >7mmol/l (>126 mg/dL) as outlined in Figure 3. The recommended first 
line oral hypoglycemic agent is metformin (IDF Clinical Guidelines Task Force, 2006). 
To ensure consistency in this analysis, costing for diabetes treatment was done using the 
common prescribed first line drug start dose, i.e. Metformin 850mg/day (NDC 
00093104910). Metformin NADAC is $0.03292 per 850mg tablet (Centers for Medicare 
& Medicaid Services, 2015a). 
Although the frequency and intensity of glucose monitoring varies depending on 
the plan of care, the IDF guidelines recommend periodic monitoring of glycated 
hemoglobin (HbA1C) in all people with type 2 diabetes as part of comprehensive 
management program (IDF Clinical Guidelines Task Force, 2006). In absence of an 
explicit monitoring schedule by the IDF guidelines, this analysis assumed twice a year 
monitoring of HbA1C in diabetic patients with stable glycemic control as recommended 
by the ADA (American Diabetes Association, 2014). The costing for the HbA1C test was 
done using CPT code 83036 QW ($13.22) in Mississippi as detailed under the absolute 
CVD risk factor approach. 
For the individual CVD risk factor approach, the high risk category (treatment 
threshold) included 464 individuals with diabetes. The annual costs for treating and 
monitoring type 2 diabetes are calculated in equation 8a-b. 
Equation 8a: Cost of treating diabetes with Metformin: 






Equation 8b: The cost of monitoring diabetes using the HbA1C test:               
HbA1C𝑡𝑒𝑠𝑡𝑎 = 464 individuals ∗ $13.22 ∗ 2 tests/year = $12268.16 
The total annual costs of diabetes management in the individual CVD risk 
approach were calculated by summing up equations 8a-b and summarized in Table 20 as 
discounted costs.  
∑  eq8a−b = $5575.3312 + $12268.16 = $17843.491  
iii. Statin and Aspirin therapy: 
In the individual CVD risk factor approach treatment with statin therapy was 
recommended for diabetics at high risk for CVD based on risk appraisal that includes 
measuring lipids and other metrics beyond the scope of this analysis. Anti-platelet 
therapy was not routinely recommended except for individuals with prior CVD events 
(not included in this analysis). Therefore, these two therapies were not included in the 
costs of the approach based on treating individual risk factors (DM/HTN). 
  The non-LB absolute CVD risk strategy treatment costs: 
 The preventive interventions employed in the non-LB absolute CVD risk strategy 
were based on the recommendations included in the WHO CVD prevention guidelines 
discussed in the methods section and outlined in Table 2. Four preventive interventions 
were costed: antihypertensive therapy, diabetes treatment and monitoring, statin therapy 
and antiplatelet therapy with aspirin. These expenses are detailed below and summarized 
as discounted costs in Table 20. 
i. Antihypertensive therapy expenses: 
Antihypertensive therapy is recommended at different thresholds based on 






antihypertensive therapy should include monotherapy with a thiazide-like diuretic or a 
CCB, which are preferred over ACEIs except in cases where hypertension coexists with 
diabetes. Antihypertensive therapy for individuals with hypertension and diabetes should 
include an ACEI combined with a thiazide-like diuretic because blacks have poor 
response to ACEIs unless combined with a thiazide diuretic (World Health Organization, 
2007).  
To ensure consistency in this analysis, the costing of the hypertension treatments 
outlined in Table 2 was done using the commonly prescribed first line drugs’ start doses, 
i.e. Hydrochlorothiazide 25mg/day for hypertensive patients without diabetes, or 
Lisinopril 10mg/day with Hydrochlorothiazide 25mg/day for hypertensive patients with 
diabetes. Hydrochlorothiazide NADAC is $0.01192 per 25mg tablet, while Lisinopril is 
$0.02011 per 10mg tablet (Medicaid.gov, 2016). The annual costs for antihypertensive 
therapy are detailed in equations 9-11 and summarized in Table 20.  
For the moderate risk category (10-20%), antihypertensive therapy was indicated 
for 487 individuals with BP>=140/90, with 80 of them having co-existing diabetes.  The 
annual costs for the antihypertensive therapy in the moderate risk category are estimated 
in equation 9a-b below: 
Equation 9a: Hypertension without comorbid diabetes 
Rxmodhtn−dm =  407 individuals ∗ $0.01192 ∗ 365 days =  $1770.76   
Equation 9b: Hypertension with comorbid diabetes 
Rxmodhtn+dm =  80 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $935.28   
For the high risk category (20-30%), antihypertensive therapy was indicated for 






annual costs for antihypertensive therapy in the high risk category/year is estimated in 
equation 10a-b below: 
Equation 10a: Hypertension without comorbid diabetes 
Rxhighhtn−dm =  193 individuals ∗ $0.01192 ∗ 365 days =  $839.70   
Equation 10b: Hypertension with comorbid diabetes 
Rxhighhtn+dm = 96 individuals ∗ ($0.01192 + $0.02011) ∗ 365days = $1122.33 
For the very high risk category (>30%), antihypertensive therapy was indicated 
for 301 individuals with BP>=130/80, with 150 of them having co-existing diabetes. The 
annual cost for treating BP>=130/80 for the very high risk category/year is estimated in 
equation 11a-b below: 
Equation 11a: Hypertension without comorbid diabetes 
Rxvhighhtn−dm =  151 individuals ∗ $0.01192 ∗ 365 days =  $656.97    
Equation 11b: Hypertension with comorbid diabetes 
Rxvhighhtn+dm = 150 individuals ∗ ($0.01192 + $0.02011) ∗ 365days = $1753.64  
The total annual costs of antihypertensive therapy in the non-LB absolute risk 
strategy were calculated by summed up costs associated with the three risk categories and 
shown in Table 20 as discounted costs.                                                                                                        
∑  eq9−11 = $1770.76 + $935.28 + $839.70 + $1122.33 + $656.97 + $1753.64 = $7078.70   
ii. Diabetes treatment and monitoring expenses: 
The WHO CVD prevention guidelines recommends pharmacotherapeutics 
treatment for type 2 diabetes to commence at the same threshold (fasting >7mmol/l or 






recommended first line oral hypoglycemic agent is Metformin 850mg/day (also used in 
the individual risk factors strategy).  
In the non-LB absolute CVD risk strategy, 431 individuals with diabetes met the 
treatment threshold discussed above (absolute risk score>=10%). The annual cost for 
treating type 2 diabetes (RxDM) in the moderate, high and very high absolute CVD risk 
categories are calculated in equation 12a. 
Equation 12a: Cost of treating diabetes with Metformin: 
 RxDM = 431 individuals ∗ $0.03292 ∗ 365 days = $5178.8098 
Since the WHO CVD prevention guidelines do not give explicit recommendations 
on the frequency of blood glucose monitoring for diabetics, in this analysis, monitoring 
of HbA1C was assumed to occur twice a year during the recommended follow-up visits 
and as recommended by the ADA. Costing for HbA1C testing was done using CMS 
clinical diagnostic laboratory fee schedule for CPT code 83036 (also used in the 
individual risk factors strategy). The annual cost for glucose monitoring (HbA1Ct) in the 
three absolute CVD risk categories/year are calculated in equation 12b. 
Equation 12b: Cost of monitoring diabetes with HbA1C test: 
 HbA1Ct = 431 individuals ∗ $13.22 ∗ 2 tests/year = $11395.64 
The total cost of diabetes management in the three absolute CVD risk categories 
were calculated by summing up equations 12a-b and summarized in Table 20 as 
discounted costs.  








iii. Statin therapy expenses: 
Treatment with statin therapy was only recommended for the very high risk 
category (>30%) when there was no mechanism to assess lipid levels (see Table 2). To 
ensure consistency in this analysis, costing was done using the common prescribed first 
line drug start dose, i.e. atorvastatin 10mg/day (NDC 00378395005). Atorvastatin 
NADAC is $0.10714 per 10mg tablet (Medicaid.gov, 2016).  
The non-LB absolute CVD risk strategy put 311 individuals in the very high risk 
category, hence qualifying them for statin therapy. The annual cost of the statin therapy 
(Rxstatin) in the very high risk category/year was estimated in equation 13 and 
summarized in Table 20 as discounted costs. 
Equation 13: Cost of statin therapy: 
Rxstatin = 311 individuals ∗ $0.10714 ∗ 365 days = $12162   
iv. Aspirin therapy expenses: 
Treatment with aspirin therapy was only recommended for the very high risk 
category (>30) as outlined in Table 2. To ensure consistency in this analysis, costing was 
done using the common first line drug start dose, i.e. enteric coated aspirin 81mg/day 
(NDC 00536100410). Aspirin NADAC is $0.01117 per 81mg tablet (Medicaid.gov, 
2016).  
The non-LB absolute CVD risk strategy put 311 individuals in the very high risk 
category thus qualifying them for antiplatelet therapy. The annual cost of the Aspirin 
therapy in the very high risk category/year was estimated in equation 14 and shown in 






Equation 13: Cost of Aspirin therapy:                                                                  
Rxasprin = 311 individuals ∗ $00.01117 ∗ 365 days = $1,267.9626 
  The non-LB absolute CVD risk strategy treatment costs: 
 The preventive interventions employed in the absolute CVD risk strategy guided 
by the LB Framingham algorithm were based on the absolute CVD risk score and 
followed the same pattern described under the non-LB absolute CVD risk strategy. 
i. Antihypertensive therapy expenses 
Antihypertensive therapy was costed using the same recommendations and 
thresholds described under the preventive strategy guided by the non-LB Framingham 
algorithm. These expenses were calculated in equations 14-16 below and summarized in 
Table 20 as discounted costs. 
For the moderate risk category (10-20%), antihypertensive therapy was indicated 
for 479 individuals with BP>=140/90, with 98 of them having co-existing diabetes.  The 
annual costs for the antihypertensive therapy in the moderate risk category/year are 
estimated in equation 14a-b. 
Equation 14a: Hypertension without comorbid diabetes 
Rxmodlhtn−dm =  381 individuals ∗ $0.01192 ∗ 365 days =  $1657.6548   
Equation 14b: Hypertension with comorbid diabetes  
Rxmodlhtn+dm =  98 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1145.7131   
For the high risk category (20-30%), antihypertensive therapy was indicated for 
252 individuals with BP>=140/90, with 89 of them having co-existing diabetes. The 







Equation 15a: Hypertension without comorbid diabetes  
Rxhighlhtn−dm =  163 individuals ∗ $0.01192 ∗ 365 days =  $709.1804   
Equation 15b: Hypertension with comorbid diabetes                       
Rxhighlhtn+dm = 89 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1040.495 
For the very high risk category (>30%), antihypertensive therapy was indicated 
for 200 individuals with BP>=130/80, with 108 of them having co-existing diabetes. The 
annual cost for treating BP>=130/80 for the very high risk category/year are estimated in 
equation 16a-b. 
Equation 16a: Hypertension without comorbid diabetes  
Rxvhighlhtn−dm =  92 individuals ∗ $0.01192 ∗ 365 days =  $400.2736    
Equation 16b: Hypertension with comorbid diabetes 
Rxvhighlhtn+dm =  108 individuals ∗ ($0.01192 + $0.02011) ∗ 365 days = $1262.622  
The total annual cost of antihypertensive therapy in all the categories above were 
calculated by summing equations 14-16 and summarized in Table 20 as discounted costs. 
∑  eq14−16 = $1657.65 + $1145.71 + $709.18 + $1040.5 + $1040.5 +
$400.27 + $1262.62 = $7256.43  
 
ii. Diabetes treatment and monitoring expenses 
In the LB absolute CVD risk strategy, 399 individuals with diabetes met the 
treatment threshold (absolute risk score >=10%). The annual costs for treating and 
monitoring type 2 diabetes (RxDMl) in the moderate, high and very high risk categories 
are calculated in equations 17a-b. 
Equation 17a: Cost of treating diabetes with Metformin: 
 RxDM𝑙 = 399 individuals ∗ $0.03292 ∗ 365 days = $4,794.30 
Equation 17b: Cost of monitoring diabetes with HbA1C test: 






The total cost of diabetes management in the three risk categories were calculated 
by summing up equations 17a-b and summarized as discounted costs in Table 20.  
∑  eq17𝑎−𝑏 = $4,794.30 + $10,549.56 = $15,343.86  
iii. Statin therapy expenses 
Treatment with statin therapy was recommended if total cholesterol was greater 
than 8 mmol/l (309 mg/dL) for the moderate risk category, and greater than 5mmol/l (193 
mg/dL) for the high risk category. In addition, everyone in the very high risk category 
(>30%) was put on statin therapy irrespective of total cholesterol levels (see Table 2).  
Based on these criteria, the LB absolute CVD risk strategy identified 25 
individuals in the moderate risk category, 250 individuals in the high risk category and 
234 individuals in the very high risk category as qualifying for statin therapy. Therefore, 
a total of 509 individuals were put on statin therapy. The associated annual cost for statin 
therapy are calculated in equation 18 and included as discounted costs in Table 20. 
Equation 18: Cost of statin therapy 
Rxstatin𝑙 = 509 individuals ∗ $0.10714 ∗ 365 days = $19,905    
iv. Aspirin therapy expenses 
Treatment with aspirin therapy was only recommended for the very high risk 
category (see Table 2). The LB absolute CVD risk strategy put 234 individuals in the 
very high risk category thus qualifying them for antiplatelet therapy. The annual cost of 
the Aspirin therapy in the very high risk category was calculated in equation 19 and 
summarized as discounted costs in Table 20. 
Equation 19: Cost of Aspirin therapy 






                 Table 20: Discounted costs of preventive interventions: Individual risk factors vs non-LB    






























































































































































































































































































































































































































    Summary of level I and II expenses 
The total costs of screening and preventive interventions prescribed for the true 
and false positives in the individual CVD risk factor program (CRxrjt) were calculated by 
summing up the costs of screening (eq. 1a), initial (eq. 2a) and follow-up (Table 19) 
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:         
CRxrjt = $14,634 + $156,135.96 +  $3,108,356 + $252,040 = $3,531,165.96 
The total costs of screening and preventive interventions prescribed for the true 
and false positives in the non-LB absolute CVD risk program (CRxajt) were calculated by 
summing up the costs of screening (eq. 1b), initial (eq. 2b) and follow-up (Table 19) 
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:         
CRxajt = $20,686 + $152,826.72 + $2,219,969 + $369,125 = $2,762,606.72 
The total costs of screening and preventive interventions prescribed for the true 
and false positives in the LB absolute CVD risk program (CRxljt) were calculated by 
summing up the costs of screening (eq. 1c), initial (eq. 2c) and follow-up (Table 19) 
office visits, and cost of pharmacotherapeutics (Table 20) as detailed below:          
CRxljt = $66,631.3 + $130,965.68 + $1,864,614 + $432,594 = $2,494,804.98 
  Level III:  Expenses in treating false negatives cases 
 The cost of secondary prevention interventions associated with each CVD 
prevention strategy was dependent on the sensitivity of the screening algorithm used. A 
screening algorithm with low sensitivity led to a high number of false negatives requiring 
treatment and rehabilitation services for the CVD events occurring in the group. Since the 






costing level III expenses was done using the average costs associated with CVD events 
in general rather than the average cost for specific CVD events.  
 Although the costs associated with treating the CVD events included in this study 
vary greatly within the US, this analysis used the estimated direct average initial and 
follow-up costs for treating CVD events in the US published by Chapman and colleagues 
in 2011 (Chapman, Liu, Girase, & Straka, 2011). In their retrospective matched cohort 
analysis of commercially insured managed care population, Chapman et al. (2011) 
estimated that initial inpatient management of a CVD event would have an average cost 
of $16,981 (SD $20,474), while the first year follow-up costs would average $16,582 (SD 
$34,425) per case.  
Due to data limitations, this analysis estimated level III expenses using these 
average direct medical and pharmacological expenses published by Chapman et al. 
(2011) despite the expected great variation in event specific costs. Although Chapman et 
al. (2011) demonstrated that the follow-up costs would increase in subsequent years of 
follow-up, this analysis assumed a constant yearly follow-up cost of $16,582 per incident 
CVD. The initial treatment costs and follow-up expenses of the false negatives associated 
with the non-LB and individual CVD risk factor approaches were depended on the year 
in which each event occurred. 
To calculate level III expenses (CUSE), the false negative cases in each year were 
multiplied by the discounted average cost of initial management of a CVD event (i.e. 
icost =1
12 [False negative cases ∗ $16,981/1.03𝑡 ]) and then the discounted average yearly 
follow-up costs were added for every subsequent follow-up year, through year 12 (i.e.  
 =1






risk approach was associated with 3 false negatives in year one. The discounted initial 
costs for year one was: 3 individuals ∗ $16,981/1.031 = $49,459.22 . The follow-up costs 
for these events was the sum of the discounted follow-up costs for each of the subsequent 
years of follow-up (see Table 21).  
Table 21: Initial & follow-up costs for treating false negative cases by prevention strategy  
 Discounted initial costs have been calculated by multiplying false negative cases with the discounted average cost of 
initial management of CVD ($16,981/1.03t) published by Chapman et al. (2011). 
Discounted follow-up (f/up) costs have been calculated by multiplying false negative cases each year with the 
discounted annual follow-up cost in subsequent years using the average cost of the first year of CVD follow-up 
($16,582/1.03t) published by Chapman et al. (2011).  
False negatives are calculated from ARIC data based on the sensitivity/specificity of the screening method used 









 Individual CVD risk 
factors program 
non-LB absolute CVD risk 
program  















$65,946 $660,229 $49,459 $495,172 $49,459 $495,172 
Yr 2 $80,031 $744,791 $32,012 $297,917 $48,019 $446,875 
Yr 3 
$46,620 $399,984 $62,160 $533,313 $77,700 $666,641 
Yr 4 $75,437 $590,766 $75,437 $590,766 $60,350 $472,613 
Yr 5 $117,184 $827,363 $58,592 $413,681 $87,888 $620,522 
Yr 6 $85,328 $534,700 $42,664 $267,350 $71,107 $445,583 
Yr 7 $27,614 $150,459 $69,036 $376,147 $69,036 $376,147 
Yr 8 $160,859 $740,961 $160,859 $740,961 $174,264 $802,708 
Yr 9 $91,102 $340,597 $65,073 $243,284 $104,116 $389,254 
Yr 10 $138,990 $395,428 $88,448 $251,636 $113,719 $323,532 
Yr 11 $159,477 $306,923 $147,209 $283,314 $147,209 $283,314 
Yr 12 $142,922 $139,563 $119,101 $116,303 $226,293 $220,975 






    Summary of level III expenses 
 The total costs of treating false negative cases in the individual CVD risk factors 
program (CUSErjt) were calculated by summing up the initial and follow-up costs in 
Table 21. 
 CUSErjt = $1,191,509 + $5,831,766 = $7,023,275  
The total costs of treating false negative cases in the non-LB absolute CVD risk 
program (CUSEajt) were calculated by summing up the initial and follow-up costs in 
Table 21.  
CUSEajt=$970,051 + $4,609,843 = $5,579,894 
The total costs of treating false negative cases in the LB absolute CVD risk 
program (CUSEljt) were calculated by summing up the initial and follow-up costs in 
Table 21. 
CUSEljt=$1,229,159 + $5,543,336 = $6,772,495 
 
 Outcomes associated with the three prevention programs 
Ideally, the effectiveness of a disease prevention program depends on the 
accuracy of the screening method used, and the potency of the prescribed preventive 
interventions. However, due to data limitations, this analysis assumed that the preventive 
interventions prescribed under the individual risk factors and absolute CVD risk 
approaches to CVD prevention were equally potent in preventing the true CVD cases 
identified by the respective screening methods. Therefore, the number of prevented CVD 
events for each preventive strategy were dependent on the sensitivity/specificity of its 






In the context of this analysis, sensitivity denotes the proportion of the observed 
(true) CVD cases that were correctly identified as positive (high risk) by a screening 
algorithm at baseline. On the other hand, specificity is the proportion of true CVD free 
cases that were correctly identified as negative (low risk) by a screening algorithm at 
baseline.  
The individual risk factors approach focusing on screening for diabetes and/or 
hypertension had its optimal balance of sensitivity/specificity at the high risk (presence of 
diabetes and/or hypertension) threshold where sensitivity is 78.05% and specificity 
45.65% as detailed in Table 16. This implies that when individuals with diabetes and/or 
hypertension are considered as positive cases, about 78% of all individuals who would 
end up experiencing CVD events during follow-up were identified at baseline. At the 
same time, about 56% if individuals who did not end up developing CVD events are 
misclassified as positive and hence unnecessarily put on preventive interventions.  
The non-LB Framingham algorithm had its optimal balance of 
sensitivity/specificity at the moderate risk (10-20%) threshold where sensitivity was 
82.04% and specificity 47.79% as detailed in Table 17. This implies that when 
individuals with >=10% absolute CVD risk score were considered as positive cases, 
about 82% of all individuals who would end up experiencing CVD events during follow-
up were correctly identified at baseline. At the same time, about 52% if individuals who 
did not end up developing CVD events were misclassified as positive cases.  
The LB Framingham algorithm had its optimal balance of sensitivity/specificity at 
the moderate risk (10-20%) threshold where sensitivity was 77.06% and specificity 






CVD risk score were considered as positive cases, about 77% of all individuals who 
would end up experiencing CVD events during follow-up were correctly identified at 
baseline. At the same time, almost 44% if individuals who did not end up developing 
CVD events were misclassified as positive cases. 
True positive cases that occurred later during follow-up were weighted less than 
those occurring early in the follow-up using the annual discounting rate of 3% discussed 
under the analysis framework. Table 22 summarizes the discounted true positives 
(predicted true CVD events) for each program.  
Table 22: True positive cases stratified by CVD prevention program 
Observed events are the CVD events that occurred each year in the at risk ARIC cohort 
Predicted true CVD events are the true positive cases calculated from ARIC data based on the  
sensitivity/specificity of the screening method used 




Individual CVD risk 
factors program 
non-LB absolute 
CVD risk program 





Predicted true CVD 
events 
Predicted true CVD 
events 
Predicted true CVD 
events 
Year actual discounted actual discounted actual discounted actual discounted 
Yr 1 20 19 16 16 17 17 17 17 
Yr 2 23 22 18 17 21 20 20 19 
Yr 3 30 27 27 25 26 24 25 23 
Yr 4 31 28 26 23 26 23 27 24 
Yr 5 33 28 25 22 29 25 27 23 
Yr 6 33 28 27 23 30 25 28 23 
Yr 7 35 28 33 27 30 24 30 24 
Yr 8 48 38 36 28 36 28 35 28 
Yr 9 36 28 29 22 31 24 28 21 
Yr 10 32 24 21 16 25 19 23 17 
Yr 11 37 27 24 17 25 18 25 18 
Yr 12 43 30 31 22 33 23 24 17 






Average and incremental cost effectiveness  
 The average cost-effectiveness ratio 
The average cost-effectiveness of each CVD prevention approach is a function of 
the net costs divided by net benefits associated with each program. These equations are 
described in equations 22-24.  







































Overall, the individual risk factors and LB absolute CVD risk 
programs had their cost-effectiveness ratios higher by 25% and 14% 
respectively compared to the non-LB absolute CVD risk program. 
Compared to the non-LB absolute CVD risk program, the 12-year 
discounted costs were 21% and 9% greater in the individual risk factors and 
LB absolute CVD risk programs respectively. Both programs identified 5% 
and 6% fewer cases respectively compared to the non-LB absolute CVD risk 






 The incremental cost-effectiveness ratio 
The incremental cost-effectiveness ratio was calculated by populating the ICER 
model with the costs and outcomes discussed in the above sections. For each CVD 
prevention strategy, the costs were calculated by adding the costs of screening, initial 
visit, discounted follow-up visits, and the discounted cost of preventive treatments 
prescribed (CRx), and the cost of treating false negatives (CUSE). The outcomes for each 
CVD prevention strategy were calculated as the discounted true positive cases and 
constitutes CVD events which could be prevented through early detection of risk 
depending on the screening algorithm used. 
The incremental cost effectiveness ratio (ICER) of the non-LB absolute CVD risk 
approach versus the individual CVD risk factor approach is calculated in equation 25.                                









+13 true positives cases
  
Interpretation: The non-LB absolute CVD risk approach would cost $2 million 
less over 12 years to identify 13 more actual CVD cases than the individual risk factors 
approach.  For every extra case that the non-LB approach identifies, it saves $170,000.  
Hence, the non-LB approach completely dominates the individual risk factors approach 
in both costs and predictive ability. 
The incremental cost effectiveness ratio (ICER) of the non-LB absolute CVD risk 
approach versus the LB absolute CVD risk approach is calculated in equation 26.                                

















Interpretation: The non-LB absolute CVD risk approach would cost $900,000 less 
over 12 years to identify 16 more actual CVD cases than the LB absolute CVD risk.  For 
every extra case that the non-LB approach identifies, it saves $58,000.  Hence, the non-








The overarching goal of this study was to externally validate and determine the 
cost-effectiveness of the non-LB Framingham algorithm in the multi-racial ARIC dataset. 
Validating and costing the non-LB Framingham algorithm in a multiracial sample with 
high representation of individuals who self-report black race was postulated to be an 
important step in availing a risk assessment tool that could guide CVD prevention in 
resource constrained settings. Important results discussed in this chapter include; the 
influence of social determinants of health on CVD risk assessment, and comparative 
predictive performance and cost-effectiveness of non-LB Framingham Algorithm. 
Social determinants of health and CVD risk assessment 
The conditions in which individuals are born, grow, live, work and age are known 
to play an important role in the evolution of many diseases including CVD (Will et al., 
2011). These social determinants of health are particularly influential in attenuating or 
exacerbating manifestation of the modifiable CVD risk factors included in this study. 
Risk assessment algorithms, such as the non-LB Framingham, that incorporate risk 
factors which are shaped by social determinants of health require an evaluation of 
relevance and validity before they are generalized across populations. 
The organizing framework used in this study appreciates the modulating impact 






comparability of effects of CVD risk factors in the white versus black US 
population. Since the social determinants of health are in part driven by distribution of 
resources, the framework also sets the stage for evaluating the feasibility of various CVD 
risk assessment strategies in resource constrained settings.  
Incidence of CVD by sex and race 
The statistical differences between the eligible and ineligible samples are expected in 
this kind of study. Since over 81% of the ineligible sample was excluded due to prevalent 
CVD at baseline, it is expected that CVD risk factors in this group was significantly 
higher than the eligible sample which was free of CVD at baseline. The higher 
percentage of blacks in the ineligible sample (36%) compared to the eligible sample 
(23%) is consistent with the known higher burden of CVD in this population.   
In the entire ARIC cohort, the incidence rate of CVD was lower but comparable to 
the Framingham cohort (11.1 versus 11.5 cases per 1000 person-years respectively). 
white women in the ARIC dataset had a significantly lower incidence rate compared to 
their counterparts in the Framingham cohort (6.5 versus 8.4 cases per 1000 person-years 
respectively).  On the other hand, white men in the ARIC cohort had a higher incidence 
rate compared to men in the Framingham cohort (15.5 versus 15.1 cases per 1000 person-
years respectively).  
The factors associated with the disparate incidence rates between the two cohorts 
could be multifaceted. One potential factor may be the manner in which the CVD 
variable is operationalized in the two studies. In the Framingham dataset the CVD 
variable included CHD, heart failure, stroke and peripheral vascular disease, however the 






result, the CVD variable in ARIC does not capture incident peripheral vascular disease. If 
the incidence rate of peripheral vascular disease in the Framingham dataset (1.2 and 2.2 
cases per 1000 person-years in women and men respectively) were to be applied in the 
ARIC cohort, the white women’s CVD incidence rate would increase slightly and be 
comparable to the rate in Framingham cohort, while white men would have a 
significantly higher CVD incident rate.  
The different incident rates among white men in ARIC versus Framingham may also 
be as a result of variation in sample characteristics. Since ethnicity was not reported in 
the ARIC dataset, there may be unaccounted differences in CVD incidence by ethnicity. 
Correspondence with NHLBI clarified that Hispanics in the ARIC sample were coded as 
black or white depending on their self-reported racial group. 
The similarity between the incidence proportion of CVD among white and black men 
in ARIC (18.6% and 18.8% respectively, p=0.900) is atypical since black men have been 
reported to have a higher incidence of CVD (R. Cooper et al., 2000; Mozaffarian et al., 
2015). If there were a significant number of Hispanic individuals in the ARIC cohort, this 
could have a negative effect on the discrimination and calibration since the Framingham 
algorithms are generally known to perform poorly among Hispanics (Beswick et al., 
2008).  
Performance of the non-LB Framingham CVD risk assessment algorithm 
 
After confirming that all covariates included in the non-LB and LB Framingham 
models met the proportionality of hazard assumption, and there was no significant 
multicollinearity between variables, sex specific Cox regression was used to test the 






specific models was critical because CVD risk factors are known to have different effect 
sizes among women and men. Just as reported in the Framingham dataset, the unadjusted 
non-LB and LB Framingham models were comparable in discrimination and calibration, 
and their performance was superior in women compared to men in the ARIC dataset.  
Among women, both the non-LB and LB Framingham models performed well, 
but among men, discrimination was low and calibration was poor for both models. The 
comparable performance of the non-LB and LB Framingham models in both sexes 
suggest that BMI could be an adequate proxy for HDL and total cholesterol in both sexes. 
The similar performance of both the non-LB and LB Framingham models in the white 
and black cohorts collaborates previous studies which have reported optimal performance 
of Framingham algorithms in the US black population. 
The discrimination of risk among women in ARIC was within the confidence 
interval reported in the Framingham dataset for the published non-LB (95% CI, 0.76-
0.81) and LB Framingham models (95% CI, 0.77-0.81). However, risk discrimination 
among men was significantly lower. The underperformance of the models among men in 
the ARIC dataset suggest that the independent variables used to predict CVD risk in the 
Framingham dataset do not capture the full extent of risk among men in the ARIC 
dataset. This phenomenon necessitates further analysis to examine the effect of the 
Framingham derived risk factors in the ARIC cohort, and additional or alternative 
variables which may improve the performance of the non-LB Framingham models. 
Evaluation of the effect and impact of the Framingham derived risk factors in the 
ARIC cohort was done by comparing the regression coefficients from the models 






score formulae. Overall, all the covariates in the non-LB and LB models had similar 
effect and impact in the black cohort, but smoking and diabetes had a different effect in 
the white cohort. The impact of smoking was higher among white women but lower 
among white men, while diabetes had a higher impact among white men in ARIC 
compared to the Framingham dataset. These differences pinpoint potential causes of the 
low performance of the non-LB and LB Framingham models among men. Since white 
men constituted 79% of the male sample in the ARIC cohort, the comparative low impact 
of smoking on CVD risk in this group may have affected the overall performance of the 
models among men. The differences also suggest that additional or alternative variable(s) 
may have a stronger explanatory power on CVD risk compared to smoking.  
The equivalence of effect of the Framingham generated risk factors in ARIC’s 
black cohort suggests that the general CVD Framingham algorithms are applicable to the 
US black population. This applicability mirrors what has been reported with earlier 
versions of Framingham algorithms which focused on hard coronary events and were 
validated in black datasets (D'Agostino RB, Grundy, Sullivan, Wilson, & CHD Risk 
Prediction Group, 2001a).  The semblance of effect of the traditional CVD risk factors in 
the black ARIC dataset and the white Framingham dataset also supports the widely 
accepted premise that traditional CVD risk factors have a fairly similar effect and impact 
across populations (Yusuf et al., 2004). These results contribute to the body of knowledge 
pertaining to CVD epidemiology in the black dataset and provide an evidence based 
foundation upon which research on novel risk factors hypothesized to have a unique 






When more CVD risk factors were added to the non-LB and LB Framingham 
models, there was no significant improvement in discrimination or calibration. In fact, 
adding more risk factors to the non-LB model (family history of premature CHD and 
waist hip ratio) and the LB model (BMI, waist hip ratio, family history of premature 
CHD, and apolipoprotein A and B) tended to increase the confidence interval of their C 
statistic without meaningful improvement in discrimination or calibration. The lack of 
significance suggests that the impact of these additional risk factors is mediated by the 
traditional risk factors already included in the published Framingham models. 
It is worth noting that some Framingham risk factors lost their statistical 
significance when additional risk factors were included. For instance, waist hip ratio 
replaced BMI as the significant variable in the adjusted non-LB model for all cohorts 
except among white women. Similarly, waist hip ratio replaced total cholesterol as the 
significant variable in the adjusted LB model among black women and men, and was 
significant among white men without affecting the significance of total cholesterol.  
The differential effect of body mass across populations has been reported 
previously. For instance, the association between high BMI and CVD mortality has been 
reported as stronger in white women than in black women (Abell et al., 2007). These 
racial differences in the effect of BMI were apparent in this analysis. Among the non-LB 
Framingham risk factors, BMI had a marginally lower effect on black women and men in 
the ARIC (β=0.668 and 0.631 respectively) compared to white women and men (β= 
0.797 and 0.793 respectively) in the ARIC dataset. 
Stepwise regression analysis revealed that other covariates in the non-LB model 






adequate discrimination among black women (C=0.7426) and BMI added no significant 
improvement (C=0.7452) to the CVD prediction model. Waist hip ratio had a slightly 
better effect than BMI among black women (C=0.7481). The waning effect of BMI when 
other traditional risk factors are held constant is consistent with the findings reported by 
Abell and colleagues. The study demonstrated that the association between obesity and 
CVD mortality was no longer significant among black women when hypertension, total 
cholesterol, diabetes, age and smoking status were controlled (Abell et al., 2007). 
These findings add to the body of literature suggesting that BMI may not be an 
optimal CVD risk indicator, and its effect could be mediated in part by other related risk 
factors such as hypertension and diabetes. Although BMI continues to be widely used as 
the metric for diagnosing overweight and obesity, there is a growing body of literature 
describing its limitations. Whereas BMI is an indicator total body fat, the metric does not 
take into consideration how the fat is distributed within the body (Simon, 2009). From a 
cardiovascular standpoint, abdominal fat is more dangerous than any other fat in the 
body.  
The slightly better performance of the waist hip ratio in the non-LB and LB 
adjusted models also adds to the body of evidence suggesting that measures of central 
adiposity may be more relevant in predicting CVD compared to measures of body mass. 
The strong predictive power of central obesity has been reported by many studies 
including the INTERHEART study where investigators demonstrated a strong link 
between increased waist hip ratio and the risk of heart attack even after controlling for the 
traditional CVD risk factors. In the same study, BMI lost its modest association with 






Despite the growing evidence supporting the significant role of central adiposity 
in predicting CVD, most of the existing non-LB algorithms have not included it as a 
covariate. Possible reasons for this may include the reported difficulties associated with 
assessing and reproducing the waist hip ratio measure (Simon, 2009). Over the last 
decade, waist circumference has been suggested as an alternative measure of central 
adiposity that still has a strong link to the risk of myocardial infarction, but is relatively 
easier to reproduce (Simon, 2009; Yusuf et al., 2005).  
The strong effect of central adiposity on CVD risk in the black population, and 
the superiority of waist hip ratio and circumference in predicting CVD provide insights 
on potential pathways to improve the non-LB Framingham algorithm. Replacing BMI 
with a measure of central adiposity such as waist circumference and testing the model in 
a large homogeneous black cohort could provide important data on the additional value 
of the measure in predicting absolute CVD risk. Other measures which could be helpful 
include the ankle brachial index which is used to diagnose peripheral vascular disease. 
Testing this measure in a homogeneous black cohort with peripheral vascular disease 
included in the CVD variable may provide insights as to whether it has any extra value in 
optimizing risk prediction of the non-LB Framingham algorithm. Evaluating the effect 
and impact of ankle branchial index was not possible in this study since peripheral 
vascular disease was not included in the CVD variable. 
  Comparative performance in risk stratification 
The comparable performance of the published non-LB and LB Framingham 
algorithms in actual risk stratification of the ARIC dataset complements the similarities 






substantial kappa statistic (0.76) suggest that the two algorithms are very comparable in 
stratification of risk. Stratification of the cohort in the high and very high risk categories 
was essentially the same for both algorithms, but the LB algorithm placed slightly more 
individuals in the low risk category. Both algorithms placed a greater proportion of men 
and blacks in higher risk categories, a trend which is consistent with current published 
CVD epidemiology (Mozaffarian et al., 2015). 
The agreement between the non-LB and LB versions of the recalibrated and the 
adjusted algorithms derived in ARIC were also high. However, the recalibrated and 
adjusted algorithms placed a significantly greater percentage of the ARIC population in 
the low risk category compared to the published Framingham non-LB algorithm. This 
discordance in risk stratification necessitated sensitivity and specificity analysis to 
determine the clinical usefulness of the non-LB Framingham algorithm, and its 
comparison with the alternative algorithms discussed above. 
The comparability of the non-LB and LB Framingham algorithm AUROC curves 
(0.706 vs 0.71 respectively) further adds to the evidence that HDL and total cholesterol 
may not add significant marginal value to CVD risk prediction especially in the black 
population. Since AUROC curves usually depict the percentage of randomly selected 
pairs for which the test correctly classifies as normal or abnormal, the AUROC of the 
non-LB algorithm manifest better performance in the ARIC dataset compared to other 
alternatives. The higher AUROC of the published non-LB Framingham algorithm 
compared to those of the recalibrated and adjusted algorithms suggest that the non-LB 






The suboptimal performance of the calibrated non-LB (AUROC=0.67) and LB 
(AUROC=0.69) based algorithms indicate that ARIC derived survival and mean of risk 
factors are not better substitutes for those generated in Framingham. This could be as a 
result of the unmeasured confounders discussed earlier, which may also have contributed 
to the low performance of the adjusted non-LB (AUROC= 0.68) and LB (AUROC= 0.69) 
based models. It is important to note that inclusion of up to 9 covariates in the adjusted 
algorithm did not make much difference in its predictive ability. 
Sensitivity/specificity analysis also revealed that the non-LB Framingham 
algorithm had a slightly better sensitivity but poorer specificity compared to the LB 
algorithm. For instance, at the high risk threshold (20-30%), the non-LB Framingham 
algorithm had sensitivity/specificity ratios of 0.25/0.95 for women and 0.51/0.73 for men. 
The LB Framingham algorithm sensitivity/specificity ratios were 0.23/0.95 for women 
and 0.50/0.75 for men respectively.  
In the Framingham dataset, the non-LB algorithm was both slightly less sensitive 
and specific compared to the LB algorithm. For example, at 20% risk threshold, 
sensitivity/specificity ratios were 0.58/0.83 for women and 0.48/85 for men versus 
0.60/0.84 for women and 0.49/85 for men in the non-LB and LB algorithms respectfully. 
(D'Agostino RB et al., 2008). These ratios indicate that in the ARIC dataset, preventive 
interventions should be initiated at least at the moderate risk category because more 
individuals who will end up developing events (true positives) was misclassified as not 
at-risk (false negatives) if the high risk category was adopted as the treatment threshold. 
Whereas the tradeoff between sensitivity and specificity are often delicate, a non-






detection of risk in the black population that carries the highest burden of CVD in the US. 
In fact, depending on availability of resources and the risk/benefit tradeoff of preventive 
treatments, a risk threshold such as the moderate risk category (10-20%) may be more 
beneficial since the non-LB Framingham algorithm would have a better overall 
sensitivity/specificity ratio (0.77/0.57) if selected as the treatment threshold in the black 
population. 
Cost-effectiveness of non-LB Framingham Algorithm 
 In the cost-effectiveness analysis where the individual CVD risk factors approach 
focusing on treating diabetes and/or hypertension was considered as the status quo, the 
non-LB absolute CVD risk approach helped detect more true CVD cases at a lower cost. 
The individual risk factors approach had a 25% higher average cost-effectiveness ratio. 
Over the 12year follow-up period, the discounted costs were 21% greater in the 
individual risk factors approach and 5% fewer CVD cases were identified.   
 Whereas the cost of screening and preventive interventions was higher in the non-
LB approach, the cost of follow-up visits and treating CVD in false negative cases was 
very high in the individual CVD risk factor approach. The high follow-up costs are as a 
result of a higher number of true and false positives, and the ‘one size fits all’ approach 
taken by the individual CVD risk factor strategy. Individuals with hypertension and/or 
diabetes were scheduled for the minimum 2 visits per year recommended by the ADA 
guidelines. Ref The non-LB absolute CVD risk approach grades the number of follow-up 
visits based on the absolute risk score. Individuals with absolute CVD risk core below 20 






for 2 visits per year. The graded approach and the fewer true and false positive cases 
scheduled for follow-up by the non-LB approach makes the approach cost-effective. 
The high number of discounted false negatives associated with the individual risk 
factors approach (13 more) further increased the costs associated with the approach due 
to the downstream expenditure of treating the resultant CVD cases. These downstream 
expenses make a strong case why using a risk assessment approach with high sensitivity 
and specificity is important. As illustrated in the methods section, clustering of multiple 
CVD risk factors is known to have an additive and synergistic effect that is not well 
captured by aggregating individual risk factors. The false negatives associated with the 
individual CVD risk factor approach occur early and are costed using lightly discounted 
treatment costs. 
The higher expenditure for screening and primary prevention interventions 
associated with the non-LB approach manifest a strategic investment in prevention with 
an overall goal of avoiding expensive downstream costs of treating CVD in the false 
negative cases. The lower follow-up costs associated with the approach reflects how the 
absolute CVD risk scores enable directing intensive interventions to those who need them 
most as widely reported in the literature (Beswick et al., 2008; Wan et al., 2009). 
In the cost-effectiveness analysis where the LB absolute CVD risk approach was 
considered as the status quo, the non-LB absolute CVD risk approach also helped detect 
more true CVD cases at a lower cost. The LB absolute CVD risk approach had a 14% 
higher average cost-effectiveness ratio. Over the 12year follow-up period, the discounted 
costs were 9% greater in the LB absolute CVD risk approach and 6% fewer CVD cases 







 The cost of screening using the LB approach was about three times higher per 
person compared to the non-LB approach, but the cost of preventive interventions was 
comparable for both strategies. The cost of follow-up visits was high in the non-LB 
absolute CVD risk approach since more individuals met the treatment threshold 
(moderate risk category) when screened using this approach.  
The high number of discounted false negatives associated with LB approach (15 
more) increased the downstream expenditure of treating the resultant CVD cases. These 
downstream expenses make a strong case why the high sensitivity associated with the 
non-LB Framingham algorithm makes it superior to the LB approach. Reducing the 
number of false negative cases cuts down expensive downstream costs.  It is important to 
point out that although the false negative cases associated with the LB approach are 
higher than the individual CVD risk factors approach, they occur later and are hence 
costed using heavily discounted treatment costs. 
The higher downstream costs also indicate that the costly screening associated 
with the LB approach was not matched with enhanced sensitivity. The slight 
improvement in specificity may be helpful in cases where false positive cases could be 
subjected to adverse therapies. However, from a cardiovascular standpoint, adverse 
effects from preventive therapies for the most part have less impact than unmitigated 
CVD risk. The lack of significant improvement in sensitivity/specificity with additional 
testing of lipids raises questions about the need for and relevance of these tests in 
predicting CVD. It is important to point out that while absolute CVD risk scores are 






against ignoring individual risk factors (World Health Organization, 2007). For instance, 
screening of lipids and other biomarkers could be helpful based on clinician’s discretion, 
especially in populations which have a tendency towards subclinical dyslipidemia 
without elevations in non-LB indicators such as BMI. 
Implementing the non-LB rather than the LB approach would save about $50,000 
for every extra true CVD case detected. The negative incremental cost-effectiveness ratio 
denotes that the non-LB approach is both more effective, and less costly compared to the 
status quo.  
 Possible relevance to sub-Saharan Africa (SSA) 
Although the global burden of disease statistics have been used to support a 
premise that SSA is exempt from the epidemic of CVD sweeping across developing 
countries, the limitations of the estimates have been detailed in various studies (R. S. 
Cooper, Osotimehin, Kaufman, & Forrester, 1998; Kariuki, Stuart-Shor, Leveille, & 
Hayman, 2015). The few rigorous studies focusing on CVD risk factors in the region 
suggest that the region may not be spared from the epidemiological transition as 
previously thought.   
Results from the STEPwise approach to Surveillance (STEPS) surveys 
commissioned by the WHO indicate that more than 75% of all STEPS participants in 
sub-Saharan Africa have had at least one major risk factor for CVD. The most prevalent 
risk factors observed across the region include: high age-adjusted BMI especially in 
women, elevated systolic blood pressure, low consumption of fruits and vegetables, and 






A Malawian national representative survey conducted in 2009 using the STEPS 
approach reported that the age-adjusted prevalence of hypertension was 33.2% in 
participants aged between 25 to 64 years. Seventy-five percent of these participants 
reported never having their blood pressure checked previously, and over 94.9% of those 
with hypertension were not aware of their condition (Msyamboza, Kathyola, Dzowela, & 
Bowie, 2012). Similar observations have been made by other researchers in sub-Saharan 
Africa who have reported high rates of hypertension, sometimes exceeding those 
observed for the same age group in developed countries (Mathenge, Foster, & Kuper, 
2010).  
These data suggest that the epidemiology of CVD in SSA may not well 
understood or appreciated in the current global burden of disease statistics. Ignoring the 
problem, as it is currently happening, would lead to missed opportunities for primary 
prevention which eventually translates to high downstream costs of treating CVD as 
demonstrated in the cost-effectiveness analysis.  
The equivalence of regression coefficients and comparability of performance 
between the blacks and whites in the US suggests that the validated non-LB Framingham 
algorithm may perform well even among groups with varying social determinants of 
health. Therefore, despite the well-known differences in social determinants of health, the 
validated non-LB Framingham algorithm may provide a beginning point for feasible 
CVD prevention in SSA pending validation studies. 
The impressive benefits of primary prevention compared to no intervention has 
been simulated for SSA. For instance, pharmacotherapeutics primary prevention efforts 






with an incremental cost-effectiveness ratio of $771 for each healthy year of life saved 
(QALY) (Gaziano, Opie, & Weinstein, 2006). Despite the current economic constraints 
in SSA, the estimated cost-effectiveness ratios for primary prevention are still considered 
feasible because they are below the WHO threshold which considers an intervention to be 
cost-effectiveness if it costs less than three times the gross national income per head to 
gain a QALY (Murray, Evans, Acharya, & Baltussen, 2000). 
 Conclusion 
Taken in total the results observed in this study demonstrate the validity and cost-
effectiveness of the non-LB Framingham CVD risk assessment algorithm.  The non-LB 
approach could provide a valuable and efficient alternative to the traditional LB-based 
approaches in the ongoing efforts to address the high burden of CVD in underserved 
communities especially the black population in the US. Due to lack of local dataset data 
or locally derived algorithms, the validated non-LB Framingham CVD risk assessment 
algorithm may provide a beginning point for initiating feasible CVD risk surveillance and 
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